Peptides, devices, and methods for the detection of anaplasma antibodies

ABSTRACT

The invention provides populations of isolated peptides useful for the detection of antibodies that bind to  Anaplasma  antigens. The peptide populations comprise peptides derived from immunogenic fragments of the  Anaplasma  Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to  Anaplasma  antigens and the diagnosis of anaplasmosis. Methods of identifying the particular  Anaplasma  species infecting a subject using the peptide populations of the invention are also disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.14/511,916, filed Oct. 10, 2014, which issued as U.S. Pat. No. 9,194,870on Nov. 24, 2015 and which claims the benefit of U.S. ProvisionalApplication No. 61/929,655, filed Jan. 21, 2014, each of which is herebyincorporated by reference in its entirety.

DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

The contents of the text file submitted electronically herewith areincorporated herein by reference in their entirety: A computer readableformat copy of the Sequence Listing (filename:ABAX_041_01US_SeqList_ST25.txt, date recorded Jul. 23, 2014, file size257 kilobytes).

BACKGROUND OF THE INVENTION

Anaplasma are a genus of gram-negative bacteria that are obligateintracellular pathogens capable of infecting granulocytes, platelets anderythrocytes in vertebrate hosts. Anaplasma bacteria are transmitted tohosts through arthropod vectors, particularly various species of ticks.A. phagocytophilum infects neutrophils and causes anaplasmosis inmammals, including humans. The incidence of human granulocytotropic (orgranulocytic) anaplasmosis (HGA, formerly known as humangranulocytotropic ehrlichiosis) has increased steadily, from 1.4 casesper million persons in 2000 to 6.1 cases per million persons in 2010. A.phagocytophilum is transmitted primarily by Ixodes spp. of ticks.Because these Ixodes species ticks also transmit Borrelia burgdorferi(the causative agent of Lyme disease), simultaneous infection with A.phagocytophilum and B. burgdorferi is common.

A. platys causes infectious cyclic thrombocytopenia by infectingplatelets and is thought to be transmitted by Rhipicephalus andDermacentor spp. ticks. Although dogs are the most common host for A.platys infection, infection in other mammals, including cats, impalas,and sheep, have been reported. Co-infection of A. platys and E. canisdue to the common vector of transmission has been known to occur.

Indirect immunofluorescence assays (IFA) and enzyme-linked immunosorbentassays (ELISA) have typically been used to detect Anaplasma infection.These assays detect the binding of anti-Anaplasma antibodies from asubject's blood, plasma, or serum to infected cells, cell lysates, orpartially purified whole Anaplasma proteins. However, these assays fordetecting anti-Anaplasma antibodies are limited in usefulness because ofsensitivity and specificity issues directly related to the nature of theAnaplasma antigens used in these tests. Although polymerase chainreaction (PCR)-based tests with improved specificity and sensitivityhave been developed, there is a continued need in the art for additionalsensitive and specific assays for detecting Anaplasma antigens andserodiagnosis of anaplasmosis.

SUMMARY OF THE INVENTION

The present invention is based, in part, on the discovery that certainsequence variants of fragments of the Anaplasma outer membrane proteinsprovide for robust detection of an antibody response against Anaplasmaspecies. Accordingly, the invention provides compositions, devices,methods, and kits useful for the detection of antibodies that bind toAnaplasma antigens and the diagnosis of anaplasmosis.

In one embodiment, the present invention provides populations ofpeptides capable of binding to antibodies that recognize Anaplasmaantigens. In certain embodiments, the population of isolated peptidescomprises three or more different peptides, wherein each peptide in thepopulation comprises a sequence of Abaxis ID 2,E-T-R-V-A-Y-P-Y-X₉-K-D-G-R-T-V-K-X₁₇-D-S-H-X₂₁-F-D-W-Q-T-P-X₂₈-P-K-X₃₁-G-F-K-D-C(SEQ ID NO: 1) or a fragment thereof, wherein X₉ is an amino acidselected from the group consisting of I, P or H, X₁₇ is an amino acidselected from the group consisting of I, W, or Y, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₈ is an amino acidselected from the group consisting of E or N, and X₃₁ is an amino acidselected from the group consisting of L or V. In other embodiments, eachpeptide in the population comprises a sequence of Abaxis ID 3,I-E-X₃-G-Y-E-X₇-F-K-T-X₁₁-G-I-R-X₁₅-S-G-T-K-E-C (SEQ ID NO: 2) or afragment thereof, wherein X₃ is an amino acid selected from the groupconsisting of L, V or A, X₇ is an amino acid selected from the groupconsisting of K, N or Q, X₁₁ is an amino acid selected from the groupconsisting of R, D, or N, and X₁₅ is an amino acid selected from thegroup consisting of E, N or Q.

In another embodiment of the invention, each peptide in the populationcomprises a sequence of APL-ID1,E-T-K-V-X₅-Y-X₇-Y-L-K-X₁₁-G-R-T-V-K-L-X₁₈-S-H-X₂₁-F-D-W-X₂₅-T-P-X₂₈-P-K-X₃₁-G-F-K-D-G-G-G-G-G-K-D-G-T-X₄₅-V-E-X₄₈-K-A-X₅₁-K-F-X₅₄-W-N-X₅₇-P-D-X₆₀-R-I-X₆₃-F-K-X₆₆-C(SEQ ID NO: 3) or a fragment thereof, wherein X₅ is an amino acidselected from the group consisting of V or A, X₇ is an amino acidselected from the group consisting of G, I or H, X₁₁ is an amino acidselected from the group consisting of E, N, or Q, X₁₈ is an amino acidselected from the group consisting of D or N, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₅ is an amino acidselected from the group consisting of Q, D, or E, X₂₈ is an amino acidselected from the group consisting of E or N, X₃₁ is an amino acidselected from the group consisting of L or V, X₄₅ is an amino acidselected from the group consisting of K or Q, X₄₈ is an amino acidselected from the group consisting of F or V, X₅₁ is an amino acidselected from the group consisting of D or N, X₅₄ is an amino acidselected from the group consisting of E or Q, X₅₇ is an amino acidselected from the group consisting of S or Q, X₆₀ is an amino acidselected from the group consisting of F or W, X₆₃ is an amino acidselected from the group consisting of I or V, and X₆₆ is an amino acidselected from the group consisting of Q or D. In yet another embodiment,each peptide in the population comprises a sequence of APL-ID2,C-K-D-G-T-X₆-V-E-X₉-K-A-X₁₂-K-F-X₁₅-W-N-X₁₈-P-D-X₂₁-R-I-X₂₄-F-K-X₂₇ (SEQID NO: 4) or a fragment thereof, wherein X₆ is an amino acid selectedfrom the group consisting of K or Q, X₉ is an amino acid selected fromthe group consisting of F or V, X₁₂ is an amino acid selected from thegroup consisting of D or N, X₁₅ is an amino acid selected from the groupconsisting of E or Q, X₁₈ is an amino acid selected from the groupconsisting of S or Q, X₂₁ is an amino acid selected from the groupconsisting of F or W, X₂₄ is an amino acid selected from the groupconsisting of I or V, and X₂₇ is an amino acid selected from the groupconsisting of Q or D. In another embodiment, each peptide in thepopulation comprises a sequence of APL-ID3,C-X₂-G-G-K-S-P-A-R-X₁₀-T-E-E-R-V-A-G-D-L-D-H-K-X₂₃-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-H(SEQ ID NO: 5) or a fragment thereof, wherein X₂ is an amino acidselected from the group consisting of I or V, X₁₀ is an amino acidselected from the group consisting of S or Y, and X₂₃ is an amino acidselected from the group consisting of E or N. In certain embodiments,each peptide in the population comprises a sequence of APL-ID5.1,C-G-K-I-L-N-L-V-S-A-V-Q-E-K-K-P-P-E-A-P-A-A-D-E-A-A-G-P-A-T-H (SEQ IDNO: 6) or a fragment thereof.

In some embodiments of the invention, a population of isolated peptidescomprises three or more different peptides, wherein each peptide in thepopulation comprises a sequence of APL-ID6,C-K-D-G-X₅-R-V-E-X₉-K-A-E-X₁₃-F-N-X₁₆-Q-X₁₈-P-N-P-X₂₂-I-K-Y-R-X₂₇ (SEQID NO: 7) or a fragment thereof, wherein X₅ is an amino acid selectedfrom the group consisting of S or Q, X₉ is an amino acid selected fromthe group consisting of F or Y, X₁₃ is an amino acid selected from thegroup consisting of R or H, X₁₆ is an amino acid selected from the groupconsisting of W or Y, X₁₈ is an amino acid selected from the groupconsisting of S or Q, X₂₂ is an amino acid selected from the groupconsisting of K or H, and X₂₇ is an amino acid selected from the groupconsisting of N or D. In another embodiment, each peptide in thepopulation comprises a sequence of APL-ID7,C-G-K-I-L-N-L-V-S-X₁₀-X₁₁-N-E-K-K-P-P-E-A-P-A-A-D-E-A-A-G-P-A-T-H (SEQID NO: 8) or a fragment thereof, wherein X₁₀ is an amino acid selectedfrom the group consisting of V, L or I, and X₁₁ is an amino acidselected from the group consisting of A or L. In still anotherembodiment, each peptide in the population comprises a sequence of APID2-1,E-T-K-V-X₅-Y-X₇-Y-L-K-X₁₁-G-R-T-V-K-L-D-S-H-X₂₁-F-D-W-X₂₅-T-P-X₂₈-P-K-X₃₁-G-F-K-D-C(SEQ ID NO: 9) or a fragment thereof, wherein X₅ is an amino acidselected from the group consisting of V or A, X₇ is an amino acidselected from the group consisting of G, I or H, X₁₁ is an amino acidselected from the group consisting of E, N, or Q, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₅ is an amino acidselected from the group consisting of Q, D, or E, X₂₈ is an amino acidselected from the group consisting of E or N, and X₃₁ is an amino acidselected from the group consisting of L or V.

In certain embodiments, the populations of Anaplasma peptides mayfurther comprise one or more antigenic peptides from another microbialspecies. In one embodiment, the population of Anaplasma peptides furthercomprises one or more antigenic peptides from an Ehrlichia species(e.g., E. canis, E. chaffeensis, E. ewingii, and E. muris), and/or aBorrelia species (e.g., B. burgdorferi, B. afzelli, or B. garinii).

Peptides of the invention may comprise at least 20, 30, 35, 40, 45, 50,or more amino acids. In some embodiments, peptides of the invention areisolated (e.g., synthetic and/or purified) peptides. In particularembodiments, peptides of the invention are conjugated to a ligand. Forexample, in certain embodiments, the peptides are biotinylated. In otherembodiments, the peptides are conjugated to streptavidin, avidin, orneutravidin. In other embodiments, the peptides are conjugated to acarrier protein (e.g., serum albumin, keyhole limpet hemocyanin (KLH),or an immunoglobulin Fc domain). In still other embodiments, thepeptides are conjugated to a dendrimer and/or are part of a multipleantigenic peptides system (MAPS). In certain embodiments, the peptidesare conjugated to a detectable entity or label, such as an enzyme, ametallic nanomaterial, or a fluorophore. In certain embodiments, thepeptides are conjugated to metallic nanoparticles, nanoshells,nanoplates, nanorings or nanorods.

In certain embodiments, peptides of the invention are attached to orimmobilized on a solid support. In one embodiment, the peptides of theinvention are attached to a solid support through a metallic nanolayer.In certain embodiments, the solid support is a bead or plurality ofbeads (e.g., a colloidal particle, metallic nanomaterial such asnanoparticle, nanoplate, or nanoshell, latex bead, etc.), a flow path ina lateral flow immunoassay device (e.g., a porous membrane), a blot(Western blot, a slot blot, or dot blot), a flow path in an analyticalor centrifugal rotor, or a tube or well (e.g., in a plate suitable foran ELISA assay).

In one aspect, the present invention provides a composition comprisingone or more populations of isolated peptides described herein.

In some embodiments, the composition comprises a population of isolatedpeptides, said population comprising three or more different peptides,wherein each peptide in the population comprises a sequence, or afragment thereof, of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, or 9.

In certain embodiments, the composition further comprises one or moreantigenic peptides from an Anaplasma species, an Ehrlichia species,and/or a Borrelia species.

In some embodiments, the composition comprises at least two differentpopulations of peptides described herein. In certain embodiments, atleast one of the peptide populations is defined by SEQ ID NO: 3. Forinstance, in one embodiment, at least one of the peptide populationscomprises three or more different peptides, wherein each peptide in thepopulation comprises a sequence, or a fragment thereof, of SEQ ID NO: 3.

In certain embodiments, the composition further comprises a secondpopulation of isolated peptides. In some embodiments, the second peptidepopulation is defined by SEQ ID NO: 7. In some other embodiments, eachpeptide in the second peptide population comprises the sequence, or afragment thereof, of SEQ ID NO: 6.

In some embodiments, the composition further comprises a thirdpopulation of isolated peptides that is different from the first andsecond peptide populations. In certain embodiments, each peptide in thethird peptide population comprises the sequence, or a fragment thereof,of SEQ ID NO: 6.

In another aspect, the present invention also provides a method fordetecting in a sample an antibody to an epitope of an Anaplasma antigen.In one embodiment, the method comprises contacting a sample with apeptide or population of peptides of the invention; and detectingformation of an antibody-peptide complex comprising the peptide or oneor more peptides in the population, wherein formation of the complex isindicative of an antibody to an epitope of an Anaplasma antigen beingpresent in the sample. The methods can be used to detect antibodies toantigens from A. phagocytophilum, A. platys, or A. marginale species.

In another embodiment, the present invention provides a method fordiagnosing anaplasmosis or cyclic thrombocytopenia in a subject. In oneembodiment, the method comprises contacting a sample from the subjectwith a peptide or population of peptides of the invention; and detectingformation of an antibody-peptide complex comprising the peptide or oneor more peptides in the population, wherein formation of the complex isindicative of the subject having anaplasmosis or cyclicthrombocytopenia.

The present invention also includes a method for identifying the speciesof Anaplasma infecting a subject. In one embodiment, the methodcomprises contacting a sample from the subject with a first peptide orfirst population of peptides and a second peptide or second populationof peptides, wherein the first peptide or first population of peptidesspecifically binds to antibodies against antigens from multipleAnaplasma species, and wherein the second peptide or second populationof peptides specifically binds to antibodies against antigens from asingle Anaplasma species; detecting formation of a firstantibody-peptide complex comprising said first peptide or one or morepeptides in the first population; and detecting formation of a secondantibody-peptide complex comprising said second peptide or one or morepeptides in the second population, wherein formation of both the firstand second antibody-peptide complexes indicates that the subject isinfected with the Anaplasma species that is specifically bound by thesecond population of isolated peptides.

In certain embodiments of the method, the first peptide or firstpopulation of peptides specifically binds to antibodies against antigensfrom A. phagocytophilum, A. platys, and A. marginale. In otherembodiments, the first peptide or first population of peptidesspecifically binds to antibodies against antigens from A.phagocytophilum and A. platys. In some embodiments, the second peptideor second population of peptides specifically binds to antibodiesagainst antigens from A. platys. In other embodiments, the secondpeptide or second population of peptides specifically binds toantibodies against antigens from A. phagocytophilum. In one embodimentof the method, the first peptide or first population of peptides isdefined by SEQ ID NO: 3 and the second peptide or second population ofpeptides is defined by SEQ ID NO: 4, and the formation of both the firstand second antibody-peptide complexes indicates that the subject isinfected with A. platys. In another embodiment of the method, the firstpeptide or first population of peptides is defined by SEQ ID NO: 3 andthe second peptide or second population of peptides is defined by SEQ IDNO: 4, and the formation of the first antibody-peptide complex, but notthe second antibody-peptide complex indicates that the subject isinfected with A. phagocytophilum.

In other embodiments, the method for identifying the species ofAnaplasma infecting a subject comprises contacting a sample from thesubject with a first population of peptides and a cell extract of asingle Anaplasma species, wherein the first population of isolatedpeptides specifically binds to antibodies against antigens from multipleAnaplasma species; detecting formation of a first antibody-peptidecomplex comprising one or more peptides in the first population; anddetecting formation of an antibody-cell extract complex comprising oneor more components in the cell extract, wherein formation of both thefirst antibody-peptide complex and the antibody-cell extract complexindicates that the subject is infected with the Anaplasma species thatproduced the cell extract.

In any of the methods described above and herein, the peptide orpopulation of peptides can, in some embodiments, be attached to orimmobilized upon a solid support. In one such embodiment, the peptide orpopulation of peptides is attached to the solid support through ametallic (e.g., gold) nanolayer. In certain embodiments, the solidsupport is a bead or plurality of beads (e.g., a colloidal particle, ametallic nanomaterial such as nanoparticle, nanoplate, nanoshell,nanorod, a latex bead, etc.), a flow path in a lateral flow immunoassaydevice (e.g., a porous membrane), a flow path in an analytical orcentrifugal rotor, a blot (Western blot, a slot blot, or dot blot), or atube or a well (e.g., in a plate suitable for an ELISA assay). In someembodiments, the solid support comprises metal, glass, a cellulose-basedmaterial (e.g., nitrocellulose), or a polymer (e.g., polystyrene,polyethylene, polypropylene, polyester, nylon, polysulfone, etc.). Inother embodiments, the peptide or population of different peptides isattached to a dendrimer and/or incorporated into a multiple antigenicpeptide system (MAPS) system. In certain other embodiments, the peptideor population of different peptides is attached to BSA, KLH, ovalbuminor a similar carrier.

In any of the methods described above and herein, the detecting step maycomprise performing an ELISA assay. In other embodiments, the detectingstep comprises performing a lateral flow immunoassay. In otherembodiments, the detecting step comprises performing an agglutinationassay. In other embodiments, the detecting step comprises spinning thesample in an analytical or centrifugal rotor. In other embodiments, thedetecting step comprises analyzing the sample using a Western blot, aslot blot, or a dot blot. In still other embodiments, the detecting stepcomprises analyzing the sample with an electrochemical sensor, anoptical sensor, or an opto-electronic sensor. In certain embodiments,the detecting step comprises performing a wavelength shift assay. Incertain embodiments, the detecting step comprises performing an IndirectFluorescent Antibody test.

The sample from the subject used in any of the methods described aboveand herein, in some embodiments, is a bodily fluid, such as blood,serum, plasma, cerebrospinal fluid, urine, mucus, or saliva. In otherembodiments, the sample is a tissue (e.g., a tissue homogenate) or acell lysate. In certain embodiments, the sample is from a wild animal(e.g., a deer or rodent, such as a mouse, chipmunk, squirrel, etc.). Inother embodiments, the sample is from a lab animal (e.g., a mouse, rat,guinea pig, rabbit, monkey, primate, etc.). In other embodiments, thesample is from a domesticated or feral animal (e.g., a dog, a cat, ahorse). In still other embodiments, the sample is from a human.

The present invention also includes kits comprising a peptide orpopulation of peptides of the invention. In one embodiment, the kitcomprises at least one population of peptides of the invention and alabeling reagent capable of binding to an antibody that recognizes anepitope of one or more peptides in the population. The labeling reagentmay be an anti-human, anti-canine, or anti-feline IgG or IgM antibodyconjugated to a detectable label. In other embodiments, the labelingreagent is protein A, protein G, and/or a protein A/G fusion proteinconjugated to a detectable label. In related embodiments, the detectablelabel is an enzyme, a metallic nanomaterial, fluorophore, or coloredlatex particle. Examples of metallic nanomaterials include, but are notlimited to, metallic nanoparticles, nanoshells, nanorings, nanorods, andnanoplates.

In certain embodiments, the peptides in the kit are attached to orimmobilized on a solid support optionally through a metallic nanolayer.In certain embodiments, the solid support is a bead (e.g., a colloidalparticle, a metallic nanomaterial such as nanoparticle, nanoplate, ornanoshell, a latex bead, etc.), a flow path in a lateral flowimmunoassay device, a flow path in an analytical or centrifugal rotor,or a tube or a well (e.g., in a plate). In some embodiments, the peptideor peptides in the kit are attached to a dendrimer and/or incorporatedinto a MAPS system. In certain other embodiments, the peptide or mixtureof different peptides is attached to BSA.

In some embodiments, the kits further comprise a population of beads ora plate (e.g., a plate suitable for an ELISA assay). In otherembodiments, the kits further comprise a device, such as a lateral flowimmunoassay device, an analytical or centrifugal rotor, a Western blot,a dot blot, a slot blot, an electrochemical sensor, an optical sensor,or an opto-electronic sensor. In certain embodiments, the population ofbeads, the plate, or the device is useful for performing an immunoassay.For example, in certain embodiments, the population of beads, the plate,or the device is useful for detecting formation of an antibody-peptidecomplex comprising an antibody from a sample and a peptide of theinvention. In certain embodiments, a peptide or population of differentpeptides of the invention is attached to or immobilized on the beads,the plate, or the device.

The kits of the invention may further comprise a set of instructionsindicating, for example, how to use a peptide or population of peptidesof the invention to detect an antibody to an Anaplasma antigen or todiagnose anaplasmosis or cyclic thrombocytopenia in a subject. Incertain embodiments, the kits comprise an instruction indicating how touse a population of beads, a plate, or a device (e.g., comprising apeptide or a population of different peptides of the invention) todetect an antibody to one or more Anaplasma antigens or to diagnoseanaplasmosis or cyclic thrombocytopenia.

Additional aspects and embodiments of the invention will be apparentfrom the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram of a double antigen sandwich assay which can be usedto detect antibodies to Anaplasma antigens. In this embodiment, peptidesof the invention are immobilized to a suitable substrate (e.g.,nitrocellulose membrane, well of an ELISA plate) at a test site.Antibodies to Anaplasma antigens in a test sample are bound by theimmobilized peptides of the invention. Test sample antibodies toappropriate Anaplasma antigens will then bind to a second set ofpeptides of the invention that are conjugated to a detectable label(e.g., metallic nanomaterial such as nanoparticle, nanoplate, ornanoshell (e.g., colloidal gold), horse radish peroxidase (HRP),alkaline phosphatase (ALP), β-galactosidase (β-GAL), fluorophore,colored latex particle, quantum dot), which detects the presence of theantibodies bound to the first set of peptides immobilized at the testsite. In certain embodiments, to amplify the detection signal, protein Aand/or protein G molecules conjugated to a detectable label (e.g.,metallic nanomaterial such as nanoparticle, nanoplate, or nanoshell(e.g., colloidal gold), HRP, ALP, β-GAL, fluorophore, colored latexparticle, quantum dot) may be applied to the test site where they willbind to the Fc region of any antibodies to Anaplasma antigens capturedby the immobilized peptides of the invention.

FIG. 2 is a diagram of one type of indirect sandwich assay which can beused to detect antibodies to Anaplasma antigens. In this embodiment,anti-human IgG/IgM, anti-dog IgG/IgM, or anti-cat IgG/IgM antibodies areimmobilized to a suitable substrate (e.g., nitrocellulose membrane, wellof an ELISA plate) at a test site. Antibodies to Anaplasma antigens in atest sample are bound by the immobilized antibodies. Test sampleantibodies to appropriate Anaplasma antigens will then bind to peptidesof the invention that are conjugated to a detectable label (e.g.,metallic nanomaterial such as nanoparticle, nanoplate, or nanoshell(e.g., colloidal gold), HRP, ALP, β-GAL, fluorophore, colored latexparticle, or quantum dot).

FIG. 3 is a diagram of another type of indirect sandwich assay which canbe used to detect antibodies to Anaplasma antigens. In this embodiment,peptides of the invention can be immobilized to a substrate (e.g.,nitrocellulose membrane, well of an ELISA plate) to captureanti-Anaplasma antibodies in a test sample. Anti-human IgG/IgM, anti-dogIgG/IgM, or anti-cat IgG/IgM antibodies conjugated to a detectable label(e.g., metallic nanomaterial such as nanoparticle, nanoplate, ornanoshell (e.g., colloidal gold), HRP, ALP, β-GAL, fluorophore, coloredlatex particle, quantum dot) can be used to detect the presence of theantibodies bound to the immobilized peptides at the test site.

FIG. 4 is a diagram of an immunoassay device which can be used to detectantibodies to Anaplasma antigens. In this embodiment of an immunoassaydevice, peptides of the invention are immobilized to a suitablesubstrate (e.g., nitrocellulose membrane, well of an ELISA plate) at atest site. Anti-Anaplasma antibodies in a test sample are bound by theimmobilized peptides of the invention. Protein A, Protein G, or aProtein A/G fusion protein conjugated to a detectable label (e.g.,metallic nanomaterial such as nanoparticle, nanoplate, or nanoshell(e.g., colloidal gold), HRP, ALP, β-GAL,fluorophore, colored latexparticle, quantum dot) is added to the system and binds to the Fcportion of the captured anti-Anaplasma antibody, thereby producing apositive signal. In this embodiment, the device can further comprise acontrol site at which binding partners that recognize the detectablelabel-conjugated protein A, detectable label-conjugated protein G,and/or detectable label-conjugated protein A/G fusion are immobilized.Such binding partners may include, but are not limited to, anti-proteinA, anti-protein G, mouse IgG, and/or other similar IgG molecules.

FIG. 5 is a line graph of ELISA scores (OD650 nm) with APL-ID1 peptidesof plasma samples drawn at various intervals from dogs infected witheither A. phagocytophilum (dog 3-13) or A. platys (dog 15-13).

FIG. 6 is a line graph of ELISA scores (OD650 nm) with APL-ID2 peptidesof plasma samples drawn at various intervals from dogs infected witheither A. phagocytophilum (dog 3-13) or A. platys (dog 15-13).

FIG. 7 depicts one example of a lateral flow assay device that can beused to detect antibodies to Anaplasma antigens. Peptides of theinvention are linked to a carrier protein (e.g. bovine serum albumin)and the resulting BSA-peptide conjugates are immobilized on anitrocellulose (NC) membrane at a test site (T). The same BSA-peptideconjugates are conjugated to a detectable label (e.g., colloidal gold)and deposited in a conjugate pad positioned upstream of the test site.Gold-conjugated protein A and gold-conjugated protein G (i.e. amplifier)is added to the conjugate pad to enhance the signal by binding to the Fcportion of the captured anti-Anaplasma antibody. The device furthercomprises a control site (C) at which binding partners that recognizethe gold-conjugated protein A and/or gold-conjugated protein G areimmobilized.

FIG. 8 illustrates the operation of the lateral flow assay device inFIG. 7. A test sample is applied to the sample port of the device andmobilizes the peptide conjugates present on the conjugate pad. Anyanti-Anaplasma antibodies present in the test sample will specificallybind to the peptide conjugates and the formed complexes will migrate tothe nitrocellulose membrane containing the test and control sites. Thelabeled peptide-antibody complexes are captured by immobilized peptidesof the invention at the test site. Gold-conjugated protein A andgold-conjugated protein G also present on the conjugate pad aremobilized by the sample and bind to the Fc regions of IgG and IgMmolecules present in the sample. Binding of the gold-conjugated proteinA and/or protein G to the captured peptide-antibody complexes amplifythe signal at the test site. Gold-conjugated protein A and/orgold-conjugated protein G is captured by a binding partner (e.g.anti-Protein A and/or anti-Protein G antibody) immobilized at thecontrol site, thereby producing a signal indicating that the device isoperational.

DETAILED DESCRIPTION

The present invention is based, in part, on the discovery that certainsequence variants of fragments of the Anaplasma outer membrane proteinsprovide for robust detection of an antibody response against Anaplasmaspecies. Accordingly, the invention provides compositions, devices,methods, and kits useful for the detection of antibodies that bind toAnaplasma antigens and for the diagnosis of anaplasmosis.

The term “antigen,” as used herein, refers to a molecule capable ofbeing recognized by an antibody. An antigen can be, for example, apeptide or a modified form thereof. An antigen can comprise one or moreepitopes.

The term “epitope,” as used herein, is a portion of an antigen that isspecifically recognized by an antibody. An epitope, for example, cancomprise or consist of a portion of a peptide (e.g., a peptide of theinvention). An epitope can be a linear epitope, sequential epitope, or aconformational epitope. In certain embodiments, epitopes may comprisenon-contiguous regions.

The terms “nucleic acid,” “oligonucleotide” and “polynucleotide” areused interchangeably herein and encompass DNA, RNA, cDNA, whether singlestranded or double stranded, as well as chemical modifications thereof.

Single letter amino acid abbreviations used herein have their standardmeaning in the art, and all peptide sequences described herein arewritten according to convention, with the N-terminal end to the left andthe C-terminal end to the right.

Compositions and Devices

The present invention provides isolated peptides capable of binding toantibodies that recognize Anaplasma antigens and devices incorporatingsuch peptides. In one embodiment, the present invention provides apopulation of isolated peptides comprising three or more differentpeptides, wherein each peptide in the population comprises a sequence ofAbaxis ID 2 (SEQ ID NO: 1), Abaxis ID 3 (SEQ ID NO: 2), APL-ID1 (SEQ IDNO: 3), APL-ID2 (SEQ ID NO: 4), APL-ID3 (SEQ ID NO: 5), APL-ID5.1 (SEQID NO: 6), APL-ID6 (SEQ ID NO: 7), APL-ID7 (SEQ ID NO: 8), APID 2-1 (SEQID NO: 9), or fragments thereof. For instance, in one embodiment, thepopulation of isolated peptides comprises three or more differentpeptides, wherein each peptide in the population comprises a sequence ofE-T-R-V-A-Y-P-Y-X₉-K-D-G-R-T-V-K-X₁₇-D-S-H-X₂₁-F-D-W-Q-T-P-X₂₈-P-K-X₃₁-G-F-K-D-C(SEQ ID NO: 1), or a fragment thereof, wherein X₉ is an amino acidselected from the group consisting of I, P or H, X₁₇ is an amino acidselected from the group consisting of I, W, or Y, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₈ is an amino acidselected from the group consisting of E or N, and X₃₁ is an amino acidselected from the group consisting of L or V.

In some embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 1, wherein X₂₈ is N and/or X₃₁ is V. In other embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 1, whereinX₉ is P, X₁₇ is I, and/or X₂₁ is N. In certain embodiments, thepopulation of isolated peptides comprises three or more peptidescomprising or consisting of any one of the sequences in Table 1.

TABLE 1 Abaxis ID 2 Peptides SEQ ID Sequence NO.E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 10E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 11E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 12E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 13 E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 14E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 15E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 16E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 17E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 18E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 19E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 20E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 21E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 22E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 23E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 24E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 25E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 26E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 27E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 28E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 29E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 30E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 31E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 32E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 33E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 34E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 35E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C 36E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 37E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 38E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 39E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 40E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 41E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 42E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 43E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 44E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 45E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 46E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 47E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 48E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 49E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 50E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 51E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 52E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 53E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 54E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 55E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 56E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 57E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 58E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 59E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 60E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 61E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 62E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 63E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 64E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 65E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 66E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 67E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 68E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 69E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 70E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 71E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 72E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 73E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 74E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 75E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 76E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 77E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 78E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 79E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 80E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 81E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 82E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 83E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 84E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 85E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 86E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 87E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 88E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 89E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-E-P-K-V-G-F-K-D-C 90E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 91E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 92E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 93E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 94E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 95E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 96E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 97E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 98E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-R-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C 99E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C100E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C101E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C102E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C103E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C104E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C105E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C106E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C107E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-D-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C108E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C109E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C110E-T-R-V-A-Y-P-Y-I-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C111E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C112E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C113E-T-R-V-A-Y-P-Y-P-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C114E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-I-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C115E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-W-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C116E-T-R-V-A-Y-P-Y-H-K-D-G-R-T-V-K-Y-D-S-H-N-F-D-W-Q-T-P-N-P-K-L-G-F-K-D-C117

In another embodiment, the population of isolated peptides comprisesthree or more different peptides, wherein each peptide in the populationcomprises a sequence of I-E-X₃-G-Y-E-X₇-F-K-T-X₁₁-G-I-R-X₁₅-S-G-T-K-E-C(SEQ ID NO: 2), or a fragment thereof, wherein X₃ is an amino acidselected from the group consisting of L, V or A, X₇ is an amino acidselected from the group consisting of K, N or Q, X₁₁ is an amino acidselected from the group consisting of R, D, or N, and X₁₅ is an aminoacid selected from the group consisting of E, N or Q. In someembodiments, peptides of the invention comprise a sequence of SEQ ID NO:2, wherein X₃ is A, and/or X₇ is N. In other embodiments, peptides ofthe invention comprise a sequence of SEQ ID NO: 2, wherein X₁₁ is R,and/or X₁₅ is Q. In particular embodiments, the population of isolatedpeptides comprises three or more peptides comprising or consisting ofany one of the sequences in Table 2.

TABLE 2 Abaxis ID 3 Peptides SEQ ID Sequence NO.I-E-L-G-Y-E-K-F-K-T-R-G-I-R-E-S-G-T-K-E-C 118I-E-L-G-Y-E-N-F-K-T-R-G-I-R-E-S-G-T-K-E-C 119I-E-L-G-Y-E-Q-F-K-T-R-G-I-R-E-S-G-T-K-E-C 120I-E-V-G-Y-E-K-F-K-T-R-G-I-R-E-S-G-T-K-E-C 121I-E-A-G-Y-E-K-F-K-T-R-G-I-R-E-S-G-T-K-E-C 122I-E-V-G-Y-E-N-F-K-T-R-G-I-R-E-S-G-T-K-E-C 123I-E-V-G-Y-E-Q-F-K-T-R-G-I-R-E-S-G-T-K-E-C 124I-E-A-G-Y-E-N-F-K-T-R-G-I-R-E-S-G-T-K-E-C 125I-E-A-G-Y-E-Q-F-K-T-R-G-I-R-E-S-G-T-K-E-C 126I-E-L-G-Y-E-K-F-K-T-R-G-I-R-E-S-G-T-K-E-C 127I-E-L-G-Y-E-N-F-K-T-D-G-I-R-E-S-G-T-K-E-C 128I-E-L-G-Y-E-Q-F-K-T-D-G-I-R-E-S-G-T-K-E-C 129I-E-V-G-Y-E-K-F-K-T-D-G-I-R-E-S-G-T-K-E-C 130I-E-A-G-Y-E-K-F-K-T-D-G-I-R-E-S-G-T-K-E-C 131I-E-V-G-Y-E-N-F-K-T-D-G-I-R-E-S-G-T-K-E-C 132I-E-V-G-Y-E-Q-F-K-T-D-G-I-R-E-S-G-T-K-E-C 133I-E-A-G-Y-E-N-F-K-T-D-G-I-R-E-S-G-T-K-E-C 134I-E-A-G-Y-E-Q-F-K-T-D-G-I-R-E-S-G-T-K-E-C 135I-E-L-G-Y-E-K-F-K-T-N-G-I-R-E-S-G-T-K-E-C 136I-E-L-G-Y-E-N-F-K-T-N-G-I-R-E-S-G-T-K-E-C 137I-E-L-G-Y-E-Q-F-K-T-N-G-I-R-E-S-G-T-K-E-C 138I-E-V-G-Y-E-K-F-K-T-N-G-I-R-E-S-G-T-K-E-C 139I-E-A-G-Y-E-K-F-K-T-N-G-I-R-E-S-G-T-K-E-C 140I-E-V-G-Y-E-N-F-K-T-N-G-I-R-E-S-G-T-K-E-C 141I-E-V-G-Y-E-Q-F-K-T-N-G-I-R-E-S-G-T-K-E-C 142I-E-A-G-Y-E-N-F-K-T-N-G-I-R-E-S-G-T-K-E-C 143I-E-A-G-Y-E-Q-F-K-T-N-G-I-R-E-S-G-T-K-E-C 144I-E-L-G-Y-E-K-F-K-T-R-G-I-R-N-S-G-T-K-E-C 145I-E-L-G-Y-E-N-F-K-T-R-G-I-R-N-S-G-T-K-E-C 146I-E-L-G-Y-E-Q-F-K-T-R-G-I-R-N-S-G-T-K-E-C 147I-E-V-G-Y-E-K-F-K-T-R-G-I-R-N-S-G-T-K-E-C 148I-E-A-G-Y-E-K-F-K-T-R-G-I-R-N-S-G-T-K-E-C 149I-E-V-G-Y-E-N-F-K-T-R-G-I-R-N-S-G-T-K-E-C 150I-E-V-G-Y-E-Q-F-K-T-R-G-I-R-N-S-G-T-K-E-C 151I-E-A-G-Y-E-N-F-K-T-R-G-I-R-N-S-G-T-K-E-C 152I-E-A-G-Y-E-Q-F-K-T-R-G-I-R-N-S-G-T-K-E-C 153I-E-L-G-Y-E-K-F-K-T-D-G-I-R-N-S-G-T-K-E-C 154I-E-L-G-Y-E-N-F-K-T-D-G-I-R-N-S-G-T-K-E-C 155I-E-L-G-Y-E-Q-F-K-T-D-G-I-R-N-S-G-T-K-E-C 156I-E-V-G-Y-E-K-F-K-T-D-G-I-R-N-S-G-T-K-E-C 157I-E-A-G-Y-E-K-F-K-T-D-G-I-R-N-S-G-T-K-E-C 158I-E-V-G-Y-E-N-F-K-T-D-G-I-R-N-S-G-T-K-E-C 159I-E-V-G-Y-E-Q-F-K-T-D-G-I-R-N-S-G-T-K-E-C 160I-E-A-G-Y-E-N-F-K-T-D-G-I-R-N-S-G-T-K-E-C 161I-E-A-G-Y-E-Q-F-K-T-D-G-I-R-N-S-G-T-K-E-C 162I-E-L-G-Y-E-K-F-K-T-N-G-I-R-N-S-G-T-K-E-C 163I-E-L-G-Y-E-N-F-K-T-N-G-I-R-N-S-G-T-K-E-C 164I-E-L-G-Y-E-Q-F-K-T-N-G-I-R-N-S-G-T-K-E-C 165I-E-V-G-Y-E-K-F-K-T-N-G-I-R-N-S-G-T-K-E-C 166I-E-A-G-Y-E-K-F-K-T-N-G-I-R-N-S-G-T-K-E-C 167I-E-V-G-Y-E-N-F-K-T-N-G-I-R-N-S-G-T-K-E-C 168I-E-V-G-Y-E-Q-F-K-T-N-G-I-R-N-S-G-T-K-E-C 169I-E-A-G-Y-E-N-F-K-T-N-G-I-R-N-S-G-T-K-E-C 170I-E-A-G-Y-E-Q-F-K-T-N-G-I-R-N-S-G-T-K-E-C 171I-E-L-G-Y-E-K-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 172I-E-L-G-Y-E-N-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 173I-E-L-G-Y-E-Q-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 174I-E-V-G-Y-E-K-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 175I-E-A-G-Y-E-K-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 176I-E-V-G-Y-E-N-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 177I-E-V-G-Y-E-Q-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 178I-E-A-G-Y-E-N-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 179I-E-A-G-Y-E-Q-F-K-T-R-G-I-R-Q-S-G-T-K-E-C 180I-E-L-G-Y-E-K-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 181I-E-L-G-Y-E-N-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 182I-E-L-G-Y-E-Q-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 183I-E-V-G-Y-E-K-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 184I-E-A-G-Y-E-K-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 185I-E-V-G-Y-E-N-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 186I-E-V-G-Y-E-Q-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 187I-E-A-G-Y-E-N-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 188I-E-A-G-Y-E-Q-F-K-T-D-G-I-R-Q-S-G-T-K-E-C 189I-E-L-G-Y-E-K-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 190I-E-L-G-Y-E-N-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 191I-E-L-G-Y-E-Q-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 192I-E-V-G-Y-E-K-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 193I-E-A-G-Y-E-K-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 194I-E-V-G-Y-E-N-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 195I-E-V-G-Y-E-Q-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 196I-E-A-G-Y-E-N-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 197I-E-A-G-Y-E-Q-F-K-T-N-G-I-R-Q-S-G-T-K-E-C 198

In certain embodiments, the population of isolated peptides comprisesthree or more different peptides, wherein each peptide in the populationcomprises a sequence ofE-T-K-V-X₅-Y-X₇-Y-L-K-X₁₁-G-R-T-V-K-L-X₁₈-S-H-X₂₁-F-D-W-X₂₅-T-P-X₂₈-P-K-X₃₁-G-F-K-D-G-G-G-G-G-K-D-G-T-X₄₅-V-E-X₄₈-K-A-X₅₁-K-F-X₅₄-W-N-X₅₇-P-D-X₆₀-R-I-X₆₃-F-K-X₆₆-C(SEQ ID NO: 3), or a fragment thereof, wherein X₅ is an amino acidselected from the group consisting of V or A, X₇ is an amino acidselected from the group consisting of G, I or H, X₁₁ is an amino acidselected from the group consisting of E, N, or Q, X₁₈ is an amino acidselected from the group consisting of D or N, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₅ is an amino acidselected from the group consisting of Q, D, or E, X₂₈ is an amino acidselected from the group consisting of E or N, X₃₁ is an amino acidselected from the group consisting of L or V, X₄₅ is an amino acidselected from the group consisting of K or Q, X₄₈ is an amino acidselected from the group consisting of F or V, X₅₁ is an amino acidselected from the group consisting of D or N, X₅₄ is an amino acidselected from the group consisting of E or Q, X₅₇ is an amino acidselected from the group consisting of S or Q, X₆₀ is an amino acidselected from the group consisting of F or W, X₆₃ is an amino acidselected from the group consisting of I or V, and X₆₆ is an amino acidselected from the group consisting of Q or D.

In related embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 3, wherein X₅ is A, X₁₈ is D, and/or X₃₁ is V. In otherembodiments, peptides of the invention comprise a sequence of SEQ ID NO:3, wherein X₄₅ is Q, X₄₈ is F, and/or X₅₁ is N. In still otherembodiments, peptides of the invention comprise a sequence of SEQ ID NO:3, wherein X₅₄ is E, X₅₇ is S, and/or X₆₀ is W. In some embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 3, whereinX₆₃ is I and/or X₆₆ is D. In particular embodiments, the population ofisolated peptides comprises three or more peptides comprising orconsisting of any one of the sequences in Table 3.

TABLE 3 APL-ID1 Peptides SEQ ID Sequence NO.E-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 199R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 200R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 201R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 202R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 203R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 204R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 205R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 206R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 207R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 208R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 209R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 210R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 211R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 212R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 213R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 214R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 215R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 216R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 217R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 218R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 219R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 220R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 221R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 222R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 223R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 224R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 225R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 226R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 227R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 228R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 229R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 230R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 231R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 232R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 233R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 234R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 235D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 236D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 237D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 238D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 239D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 240D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 241D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 242D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 243D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 244D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 245D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 246D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 247D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 248D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 249D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 250D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 251D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 252D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 253D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 254D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 255D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 256D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 257D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 258D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 259D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 260D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 261D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 262D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-GK-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 263D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 264D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 265D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 266D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 267D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 268D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 269D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 270D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 271N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 272N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 273N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 274N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 275N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 276N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 277N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 278N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 279N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 280N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 281N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 282N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 283N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 284N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 285N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 286N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 287N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H- 288N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 289N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 290N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 291N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-N-S-H- 292N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-N-S-H- 293N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-N-S-H- 294N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 295N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 296N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 297N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-N-S-H- 298N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-N-S-H- 299N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-N-S-H- 300N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 301N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 302N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 303N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 304N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 305N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-N-S-H- 306N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-Q-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 307R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-d-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 308R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 309R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 310R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 311R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 312R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 313R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 314R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 315R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 316R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-I-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 317R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 318R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 319R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 320R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 321R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 322R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 323R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 324R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 325R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 326R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 327R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 328R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 329R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 330R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 331R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 332R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 333R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 334R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 335R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 336R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 337R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 338R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 339R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 340R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 341R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H- 342R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 343R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H- 344R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H- 345R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H- 346R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 347R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 348R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H- 349R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-CE-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H- 350R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-G-G-G-G-G-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-W- R-I-V-F-K-D-C

In some embodiments, the population of isolated peptides comprises threeor more different peptides, wherein each peptide in the populationcomprises a sequence ofC-K-D-G-T-X₆-V-E-X₉-K-A-X₁₂-K-F-X₁₅-W-N-X₁₈-P-D-X₂₁-R-I-X₂₄-F-K-X₂₇ (SEQID NO: 4), or a fragment thereof, wherein X₆ is an amino acid selectedfrom the group consisting of K or Q, X₉ is an amino acid selected fromthe group consisting of F or V, X₁₂ is an amino acid selected from thegroup consisting of D or N, X₁₅ is an amino acid selected from the groupconsisting of E or Q, X18 is an amino acid selected from the groupconsisting of S or Q, X₂₁ is an amino acid selected from the groupconsisting of F or W, X₂₄ is an amino acid selected from the groupconsisting of I or V, and X₂₇ is an amino acid selected from the groupconsisting of Q or D. In related embodiments, peptides of the inventioncomprise a sequence of SEQ ID NO: 4, wherein X₆ is Q, X₉ is F, and/orX₁₂ is N. In other embodiments, peptides of the invention comprise asequence of SEQ ID NO: 4, wherein X₁₅ is E, X₁₈ is S, and/or X₂₁ is W.In still other embodiments, peptides of the invention comprise asequence of SEQ ID NO: 4, wherein X₂₄ is I and/or X₂₇ is D. Inparticular embodiments, the population of isolated peptides comprisesthree or more peptides comprising or consisting of any one of thesequences in Table 4.

TABLE 4 APL-ID2 Peptides Sequence SEQ ID NO.C-K-D-G-T-K-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 351C-K-D-G-T-K-V-E-V-K-A-D-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 352C-K-D-G-T-Q-V-E-F-K-A-D-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 353C-K-D-G-T-Q-V-E-V-K-A-D-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 354C-K-D-G-T-K-V-E-F-K-A-N-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 355C-K-D-G-T-K-V-E-V-K-A-N-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 356C-K-D-G-T-Q-V-E-F-K-A-N-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 357C-K-D-G-T-Q-V-E-V-K-A-N-K-F-E-W-N-S-P-D-F-R-I-I-F-K-Q 358C-K-D-G-T-K-V-E-F-K-A-D-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 359C-K-D-G-T-K-V-E-V-K-A-D-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 360C-K-D-G-T-Q-V-E-F-K-A-D-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 361C-K-D-G-T-Q-V-E-V-K-A-D-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 362C-K-D-G-T-K-V-E-F-K-A-N-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 363C-K-D-G-T-K-V-E-V-K-A-N-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 364C-K-D-G-T-Q-V-E-F-K-A-N-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 365C-K-D-G-T-Q-V-E-V-K-A-N-K-F-Q-W-N-S-P-D-F-R-I-I-F-K-Q 366C-K-D-G-T-K-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 367C-K-D-G-T-K-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 368C-K-D-G-T-Q-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 369C-K-D-G-T-Q-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 370C-K-D-G-T-K-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 371C-K-D-G-T-K-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 372C-K-D-G-T-Q-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 373C-K-D-G-T-Q-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-F-R-I-I-F-K-Q 374C-K-D-G-T-K-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 375C-K-D-G-T-K-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 376C-K-D-G-T-Q-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 377C-K-D-G-T-Q-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 378C-K-D-G-T-K-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 379C-K-D-G-T-K-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 380C-K-D-G-T-Q-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 381C-K-D-G-T-Q-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-I-F-K-Q 382C-K-D-G-T-K-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 383C-K-D-G-T-K-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 384C-K-D-G-T-Q-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 385C-K-D-G-T-Q-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 386C-K-D-G-T-K-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 387C-K-D-G-T-K-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 388C-K-D-G-T-Q-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 389C-K-D-G-T-Q-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-Q 390C-K-D-G-T-K-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 391C-K-D-G-T-K-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 392C-K-D-G-T-Q-V-E-F-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 393C-K-D-G-T-Q-V-E-V-K-A-D-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 394C-K-D-G-T-K-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 395C-K-D-G-T-K-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 396C-K-D-G-T-Q-V-E-F-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 397C-K-D-G-T-Q-V-E-V-K-A-N-K-F-Q-W-N-Q-P-D-W-R-I-V-F-K-D 398

In another embodiment of the invention, the population of isolatedpeptides comprises three or more different peptides, wherein eachpeptide in the population comprises a sequence ofC-X₂-G-G-K-S-P-A-R-X₁₀-T-E-E-R-V-A-G-D-L-D-H-K-X₂₃-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-H(SEQ ID NO: 5), or a fragment thereof, wherein X₂ is an amino acidselected from the group consisting of I or V, X₁₀ is an amino acidselected from the group consisting of S or Y, and X₂₃ is an amino acidselected from the group consisting of E or N. In related embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 5, whereinX₂ is V. In other embodiments, peptides of the invention comprise asequence of SEQ ID NO: 5, wherein X₁₀ is Y. In still other embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 5, whereinX₂₃ is E. In some embodiments, the population of isolated peptidescomprises three or more peptides comprising or consisting of any one ofthe sequences in Table 5.

TABLE 5 APL-ID3 Peptides SEQ ID Sequence NO.C-I-G-G-K-S-P-A-R-S-T-E-E-R-V-A-G-D-L-D-H- 399K-E-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-I-G-G-K-S-P-A-R-Y-T-E-E-R-V-A-G-D-L-D-H- 400K-E-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-V-G-G-K-S-P-A-R-S-T-E-E-R-V-A-G-D-L-D-H- 401K-E-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-V-G-G-K-S-P-A-R-Y-T-E-E-R-V-A-G-D-L-D-H- 402K-E-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-I-G-G-K-S-P-A-R-S-T-E-E-R-V-A-G-D-L-D-H- 403K-N-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-I-G-G-K-S-P-A-R-Y-T-E-E-R-V-A-G-D-L-D-H- 404K-N-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-V-G-G-K-S-P-A-R-S-T-E-E-R-V-A-G-D-L-D-H- 405K-N-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-HC-V-G-G-K-S-P-A-R-Y-T-E-E-R-V-A-G-D-L-D-H- 406K-N-V-D-S-D-K-K-H-D-A-E-K-T-E-E-K-R-H

In one embodiment, the peptides of the invention comprise a sequence ofC-G-K-I-L-N-L-V-S-A-V-Q-E-K-K-P-P-E-A-P-A-A-D-E-A-A-G-P-A-T-H (SEQ IDNO: 6), or a fragment thereof. The population of isolated peptides maycomprise three or more peptides, each peptide comprising a sequence ofSEQ ID NO: 6 or fragments of this sequence. In some embodiments,peptides comprising the sequence of SEQ ID NO: 6 may be included inother peptide populations of the invention described herein.

In another embodiment of the invention, the population of isolatedpeptides comprises three or more different peptides, wherein eachpeptide in the population comprises a sequence ofC-K-D-G-X₅-R-V-E-X₉-K-A-E-X₁₃-F-N-X₁₆-Q-X₁₈-P-N-P-X₂₂-I-K-Y-R-X₂₇ (SEQID NO: 7), or a fragment thereof, wherein X₅ is an amino acid selectedfrom the group consisting of S or Q, X₉ is an amino acid selected fromthe group consisting of F or Y, X₁₃ is an amino acid selected from thegroup consisting of R or H, X₁₆ is an amino acid selected from the groupconsisting of W or Y, X₁₈ is an amino acid selected from the groupconsisting of S or Q, X₂₂ is an amino acid selected from the groupconsisting of K or H, and X₂₇ is an amino acid selected from the groupconsisting of N or D.

In related embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 7, wherein X₅ is Q, X₉ is Y, and/or X₁₃ is H. In otherembodiments, peptides of the invention comprise a sequence of SEQ ID NO:7, wherein X₁₆ is W and/or X₂₂ is K. In still other embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 7, whereinX₁₈ is S and/or X₂₇ is D. In some embodiments, the population ofisolated peptides comprises three or more peptides comprising orconsisting of any one of the sequences in Table 6.

TABLE 6 APL-ID6 Peptides Sequence SEQ ID NO.C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 407C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 408C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 409C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 410C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 411C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 412C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 413C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-W-Q-S-P-N-P-K-I-K-Y-R-N 414C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 415C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 416C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 417C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 418C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 419C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 420C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 421C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-Y-Q-S-P-N-P-K-I-K-Y-R-N 422C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 423C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 424C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 425C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 426C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 427C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 428C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 429C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-W-Q-Q-P-N-P-K-I-K-Y-R-N 430C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 431C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 432C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 433C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 434C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 435C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 436C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 437C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-K-I-K-Y-R-N 438C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-W-Q-Q-P-N-P-H-I-K-Y-R-N 439C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-W-Q-Q-P-N-P-H-I-K-Y-R-N 440C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 441C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 442C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 443C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 444C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 445C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 446C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 447C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-N 448C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-W-Q-Q-P-N-P-H-I-K-Y-R-D 449C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-W-Q-Q-P-N-P-H-I-K-Y-R-D 450C-K-D-G-S-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 451C-K-D-G-S-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 452C-K-D-G-Q-R-V-E-F-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 453C-K-D-G-Q-R-V-E-Y-K-A-E-R-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 454C-K-D-G-S-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 455C-K-D-G-S-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 456C-K-D-G-Q-R-V-E-F-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 457C-K-D-G-Q-R-V-E-Y-K-A-E-H-F-N-Y-Q-Q-P-N-P-H-I-K-Y-R-D 458

In some embodiments of the invention, the population of isolatedpeptides comprises three or more different peptides, wherein eachpeptide in the population comprises a sequence ofC-G-K-I-L-N-L-V-S-X₁₀-X₁₁-N-E-K-K-P-P-E-A-P-A-A-D-E-A-A-G-P-A-T-H (SEQID NO: 8), or a fragment thereof, wherein X₁₀ is an amino acid selectedfrom the group consisting of V, L or I, and X₁₁ is an amino acidselected from the group consisting of A or L. In such embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 8, whereinX₁₁ is A. In other embodiments, peptides of the invention comprise asequence of SEQ ID NO: 8, wherein X₁₀ is I. In still other embodiments,the population of isolated peptides comprises three or more peptidescomprising or consisting of any one of the sequences in Table 7.

TABLE 7 APL-ID7 Peptides Sequence SEQ ID NO.C-G-K-I-L-N-L-V-S-V-A-N-E-K-K-P-P-E-A- 459 P-A-A-D-E-A-A-G-P-A-T-HC-G-K-I-L-N-L-V-S-V-L-N-E-K-K-P-P-E-A- 460 P-A-A-D-E-A-A-G-P-A-T-HC-G-K-I-L-N-L-V-S-L-A-N-E-K-K-P-P-E-A- 461 P-A-A-D-E-A-A-G-P-A-T-HC-G-K-I-L-N-L-V-S-L-L-N-E-K-K-P-P-E-A- 462 P-A-A-D-E-A-A-G-P-A-T-HC-G-K-I-L-N-L-V-S-I-A-N-E-K-K-P-P-E-A- 463 P-A-A-D-E-A-A-G-P-A-T-HC-G-K-I-L-N-L-V-S-I-L-N-E-K-K-P-P-E-A- 464 P-A-A-D-E-A-A-G-P-A-T-H

In other embodiments of the invention, the population of isolatedpeptides comprises three or more different peptides, wherein eachpeptide in the population comprises a sequence ofE-T-K-V-X₅-Y-X₇-Y-L-K-X₁₁-G-R-T-V-K-L-D-S-H-X₂₁-F-D-W-X₂₅-T-P-X₂₈-P-K-X₃₁-G-F-K-D-C(SEQ ID NO: 9), or a fragment thereof, wherein X₅ is an amino acidselected from the group consisting of V or A, X₇ is an amino acidselected from the group consisting of G, I or H, X₁₁ is an amino acidselected from the group consisting of E, N, or Q, X₂₁ is an amino acidselected from the group consisting of R, D, or N, X₂₅ is an amino acidselected from the group consisting of Q, D, or E, X₂₈ is an amino acidselected from the group consisting of E or N, and X₃₁ is an amino acidselected from the group consisting of L or V.

In related embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 9, wherein X₅ is V, X₇ is G, and/or X₁₁ is N. In otherembodiments, peptides of the invention comprise a sequence of SEQ ID NO:9, wherein X₂₁ is R and/or X₂₅ is E. In still other embodiments,peptides of the invention comprise a sequence of SEQ ID NO: 9, whereinX₂₈ is N and/or X₃₁ is L. In some embodiments, the population ofisolated peptides comprises three or more peptides comprising orconsisting of any one of the sequences in Table 8.

TABLE 8 APID 2-1 Peptides SEQ ID Sequence NO.E-T-K-V-V-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C465E-T-K-V-V-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C466E-T-K-V-V-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C467E-T-K-V-A-Y-G-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C468E-T-K-V-A-Y-I-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C469E-T-K-V-A-Y-H-Y-L-K-E-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C470E-T-K-V-V-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C471E-T-K-V-V-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C472E-T-K-V-V-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C473E-T-K-V-A-Y-G-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C474E-T-K-V-A-Y-I-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C475E-T-K-V-A-Y-H-Y-L-K-N-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C476E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C477E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C478E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C479E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C480E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C481E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-R-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C482E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C483E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C484E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C485E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C486E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C487E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C488E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C489E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C490E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C491E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C492E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C493E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-Q-T-P-E-P-K-L-G-F-K-D-C494E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C495E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C496E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C497E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C498E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C499E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C500E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C501E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C502E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C503E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C504E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C505E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-D-T-P-E-P-K-L-G-F-K-D-C506E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C507E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C508E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C509E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C510E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C511E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C512E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C513E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C514E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C515E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C516E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C517E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-E-P-K-L-G-F-K-D-C518E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C519E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C520E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C521E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C522E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C523E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C524E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C525E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C526E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C527E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C528E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C529E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-L-G-F-K-D-C530E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C531E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C532E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C533E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C534E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C535E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-D-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C536E-T-K-V-V-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C537E-T-K-V-V-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C538E-T-K-V-V-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C539E-T-K-V-A-Y-G-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C540E-T-K-V-A-Y-I-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C541E-T-K-V-A-Y-H-Y-L-K-Q-G-R-T-V-K-L-D-S-H-N-F-D-W-E-T-P-N-P-K-V-G-F-K-D-C542

In certain embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9 and anadditional N-terminal peptide sequence (e.g., an N-terminal extension).The additional N-terminal peptide sequence can comprise 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more amino acids. Incertain embodiments, the N-terminal peptide sequence has a length ofabout 5 to about 10, about 10 to about 15, about 15 to about 20, about20 to about 25, about 25 to about 30, about 30 to about 40, or about 40to about 50 amino acids. In one embodiment, the N-terminal peptidesequence can be one or more linking residues (e.g. one or more glycine,cysteine, or serine residues). For instance, in certain embodiments, thecarboxyl-terminal cysteine residue in any of the sequences describedherein can be located at the amino terminus instead. In a similarmanner, the amino-terminal cysteine residue in any of the sequencesdescribed herein can be located at the carboxyl terminus instead.

The additional N-terminal peptide sequence can be a native sequence. Asused herein, a “native” sequence is a peptide sequence from anaturally-occurring Anaplasma major surface protein 2 (MSP2)/p44 orOMP/p44 sequence, or a variant thereof. In certain embodiments, thepeptide sequence is a fragment of a naturally-occurring Anaplasma MSP2/p44 or OMP/p44 sequence. The peptide sequence can be, e.g., from aconserved or non-conserved region of MSP 2/p44 or OMP/p44. The peptidesequence can comprise, e.g., an epitope, such as an immunodominantepitope or any other epitope recognizable by a host (e.g., human, dog,etc.) immune system. Anaplasma MSP 2/p44 or OMP/p44 proteins andpeptides thereof have been described, e.g., in Genebank Accession Nos.AAO30097.1, ACV85580.1, ACV85559.1, AEH96270.1, ADU56850.1, AEH96270.1,and AAQ91849.1 as well as in U.S. Pat. Nos. 7,507,789, 8,303,959,8,158,370, and U.S. Patent Publication No. 2013/0064842, the contents ofeach of which are incorporated herein by reference in their entireties.

Variant polypeptides are at least about 80, 85, 90, 95, 98, or 99%identical to a peptide shown in SEQ ID NOs: 1-543 and are alsopolypeptides of the invention. Percent sequence identity has an artrecognized meaning and there are a number of methods to measure identitybetween two polypeptide or polynucleotide sequences. See, e.g., Lesk,Ed., Computational Molecular Biology, Oxford University Press, New York,(1988); Smith, Ed., Biocomputing: Informatics And Genome Projects,Academic Press, New York, (1993); Griffin & Griffin, Eds., ComputerAnalysis Of Sequence Data, Part I, Humana Press, New Jersey, (1994); vonHeinje, Sequence Analysis In Molecular Biology, Academic Press, (1987);and Gribskov & Devereux, Eds., Sequence Analysis Primer, M StocktonPress, New York, (1991). Methods for aligning polynucleotides orpolypeptides are codified in computer programs, including the GCGprogram package (Devereux et al., Nuc. Acids Res. 12:387 (1984)),BLASTP, BLASTN, FASTA (Atschul et al., J Molec. Biol. 215:403 (1990)),and Bestfit program (Wisconsin Sequence Analysis Package, Version 8 forUnix, Genetics Computer Group, University Research Park, 575 ScienceDrive, Madison, Wis. 53711) which uses the local homology algorithm ofSmith and Waterman (Adv. App. Math., 2:482-489 (1981)). For example, thecomputer program ALIGN which employs the FASTA algorithm can be used,with an affine gap search with a gap open penalty of −12 and a gapextension penalty of −2.

When using any of the sequence alignment programs to determine whether aparticular sequence is, for instance, about 95% identical to a referencesequence, the parameters are set such that the percentage of identity iscalculated over the full length of the reference polynucleotide and thatgaps in identity of up to 5% of the total number of nucleotides in thereference polynucleotide are allowed.

Variants of the peptide sequences can be readily selected by one ofskill in the art, based in part on known properties of the sequence. Forexample, a variant peptide can include amino acid substitutions (e.g.,conservative amino acid substitutions) and/or deletions (e.g., small,single amino acid deletions, or deletions encompassing 2, 3, 4, 5, 10,15, 20, or more contiguous amino acids). Thus, in certain embodiments, avariant of a native peptide sequence is one that differs from anaturally-occurring sequence by (i) one or more (e.g., 2, 3, 4, 5, 6, ormore) conservative amino acid substitutions, (ii) deletion of 1 or more(e.g., 2, 3, 4, 5, 6, or more) amino acids, or (iii) a combinationthereof. Deleted amino acids can be contiguous or non-contiguous.Conservative amino acid substitutions are those that take place within afamily of amino acids that are related in their side chains and chemicalproperties. These include, e.g., (1) acidic amino acids: aspartate,glutamate; (2) basic amino acids: lysine, arginine, histidine; (3)nonpolar amino acids: alanine, valine, leucine, isoleucine, proline,phenylalanine, methionine, tryptophan; (4) uncharged polar amino acids:glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine;(5) aliphatic amino acids: glycine, alanine, valine, leucine,isoleucine, serine, threonine, with serine and threonine optionallygrouped separately as aliphatic-hydroxyl; (6) aromatic amino acids:phenylalanine, tyrosine, tryptophan; (7) amide amino acids: asparagine,glutamine; and (9) sulfur-containing amino acids: cysteine andmethionine. See, e.g., Biochemistry, 2nd ed., Ed. by L. Stryer, W HFreeman and Co.: 1981. Methods for confirming that variant peptides aresuitable are conventional and routine.

Variants of the peptide sequences encompass variations on previouslydefined peptide sequences. For example, a previously described peptidesequence comprising a known epitope may be lengthened or shortened, atone or both ends (e.g., by about 1-3 amino acids), and/or one, two,three, four or more amino acids may be substituted by conservative aminoacids, etc. Furthermore, if a region of a protein has been identified ascontaining an epitope of interest, an investigator can “shift” theregion of interest (e.g., by about 5 amino acids in either direction)from the endpoints of the original rough region to optimize theactivity.

In certain embodiments, the additional N-terminal peptide sequence cancomprise or consist of another peptide having a sequence of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6,SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. Thus, in some embodiments,a peptide of the invention can be a multimer of sequences having asequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. Inother embodiments, the N-terminal peptide sequence is a native MSP 2/p44or OMP/p44 peptide sequence that is naturally adjacent to the N-terminalend of a sequence of any one of SEQ ID NOs: 1 to 9. In otherembodiments, the peptide can comprise a fusion of sequences of any oneof SEQ ID NOs: 1 to 9 optionally through one or more linking aminoacids. For example, in one embodiment, the peptide can comprise asequence of SEQ ID NO: 1 or SEQ ID NO: 2 linked to SEQ ID NO: 4optionally through one or more linking amino acids (e.g. glycine,serine, or cysteine residues). In another embodiment, the peptide cancomprise a sequence of SEQ ID NO: 5 linked to SEQ ID NO: 4 or SEQ ID NO:6 optionally through one or more linking amino acids (e.g. glycine,serine, or cysteine residues). In another embodiment, the peptide cancomprise a sequence of SEQ ID NO: 9 linked to SEQ ID NO: 4, SEQ ID NO:7, or SEQ ID NO: 8 optionally through one or more linking amino acids(e.g. glycine, serine, or cysteine residues).

In certain embodiments, the additional N-terminal peptide sequence is anon-native sequence. As used herein, a “non-native” sequence is anyprotein sequence, whether from an Anaplasma protein or otherwise, otherthan a native MSP 2/p44 or OMP/p44 peptide sequence. In certainembodiments, the additional N-terminal peptide sequence comprises anepitope of an Anaplasma surface antigen. Other Anaplasma antigensinclude, but are not limited to MSP5 , HSP60, Asp14 (Kahlon et al.,Infect Immun., Vol. 81(1): 65-79, 2013), and the antigens described inZhi et al., J. Clin. Microbiol., Vol. 35(10): 2606-2611, 1997.Polypeptides or peptides derived from other microorganisms can also beused, including Ehrlichia antigens and Borrelia antigens. Protein andpeptide sequences corresponding to Ehrlichia antigens have beendescribed. See, e.g., U.S. application Ser. No. 14/052,296, U.S. Pat.Nos. 6,306,402, 6,355,777, 7,204,992, 7,407,770, 8,828,675, andWO2006/138509, the contents of each of which are incorporated herein byreference in their entireties. Protein and peptide sequencescorresponding to Borrelia antigens have been described. See, e.g., U.S.Pat. Nos. 6,716,574, 5,618,533, 5,643,733, 5,643,751, 5,932,220,6,617,441, 7,887,815, 8,568,989, and 8,758,772, the contents of each ofwhich are incorporated herein by reference in their entireties.

In certain embodiments, the additional N-terminal peptide sequence is acombination of sequences. For example, the additional N-terminal peptidesequence can comprise a native sequence, a non-native sequence, or anycombination of such sequences (e.g., two or more native sequences, twoor more non-native sequences, or one or more native sequences incombination with one or more non-native sequences).

In certain embodiments, peptides of the invention comprise a sequence ofSEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9 and anadditional C-terminal sequence (e.g., a C-terminal extension). Theadditional C-terminal peptide sequence can comprise 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or more amino acids. In certainembodiments, the additional C-terminal sequence has a length of about 5to about 10, about 10 to about 15, about 15 to about 20, about 20 toabout 25, about 25 to about 30, about 30 to about 40, or about 40 toabout 50 amino acids. The additional C-terminal peptide sequence can bea native MSP 2/p44 or OMP/p44 sequence. In certain embodiments, theC-terminal peptide sequence is a fragment of a naturally-occurringAnaplasma MSP 2/p44 or OMP/p44 sequence. The peptide sequence can be,e.g., from a conserved or non-conserved region of MSP 2/p44 or OMP/p44.The peptide sequence can comprise, e.g., an epitope, such as animmunodominant epitope or any other epitope recognizable by a host(e.g., human, dog, etc.) immune system.

In certain embodiments, the additional C-terminal peptide sequence cancomprise or consist of another peptide having a sequence of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6,SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. For example, in certainembodiments, a peptide of the invention can be a multimer of sequenceseach having a sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQID NO: 9. In other embodiments, the native sequence is a sequence (e.g.,a MSP 2/p44 or OMP/p44 sequence) that is naturally adjacent to theC-terminal end of a sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8,or SEQ ID NO: 9.

In certain embodiments, the additional C-terminal peptide sequence is anon-native sequence. In some embodiments, the additional C-terminalpeptide sequence comprises an epitope of an Anaplasma surface antigenother than MSP 2/p44 or OMP/p44. Polypeptides or peptides derived fromother microorganisms can also be used. For instance, in someembodiments, the Anaplasma peptide sequence can further comprise anepitope from an Ehrlichia or Borrelia antigen.

In certain embodiments, the additional C-terminal peptide sequence is acombination of sequences. For example, the additional C-terminal peptidesequence can comprise a native, a non-native sequence, or anycombination of such sequences (e.g., two or more native sequences, twoor more non-native sequences, or one or more native sequences incombination with one or more non-native sequences).

In certain embodiments, peptides of the invention comprise a sequencedefined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9 andfurther comprise an additional N-terminal peptide sequence and anadditional C-terminal peptide sequence. The additional N-terminal andC-terminal peptide sequences can be as described above. Peptides of theinvention generally do not consist of a full-length MSP 2/p44 or OMP/p44protein. However, in certain embodiments, peptides of the invention cancomprise a full-length MSP 2/p44 or OMP/p44 protein. In otherembodiments, peptides of the invention do not comprise a full-length MSP2/p44 or OMP/p44 protein.

A peptide of the invention comprising an additional N-terminal and/orC-terminal peptide sequence can be designed for diagnosing Anaplasmainfections (e.g. anaplasmosis) early after infection (e.g., within oneto two weeks after the onset of infection). For example, in certainembodiments, the additional N-terminal and/or C-terminal peptidesequence comprises an antigen or epitope associated with early stages ofAnaplasma infection.

In addition to the sequences described above, the additional N-terminaland C-terminal sequences can comprise or consist of a flexible sequence,designed to better present the peptides of the invention for detectionin an immunoassay (e.g., ELISA assay, lateral flow immunoassay,agglutination assay, etc.). Such flexible sequences can be readilyidentified by persons skilled in the art.

In certain embodiments, peptides of the invention comprise or consist of20 or more (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 30 or more (e.g., 31, 32, 33, 34, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 35 or more (e.g., 36, 37, 38, 39, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 40 or more (e.g., 41, 42, 43, 44, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 45 or more (e.g., 46, 47, 48, 49, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 50 or more (e.g., 51, 52, 53, 54, or more) aminoacid residues. In certain embodiments, peptides of the inventioncomprise or consist of 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or moreamino acid residues. In some embodiments, peptides of the inventioncomprise or consist of about 20 to about 75 amino acids, about 25 toabout 65 amino acids, or about 30 to about 55 amino acids.

In certain embodiments, peptides of the invention comprise an epitope ofa peptide sequence described herein. For example, in certainembodiments, peptides of the invention comprise an epitope of a sequenceselected from the group consisting of SEQ ID NOs: 1-543.

In some embodiments, peptides of the invention comprise a fragment of apeptide sequence described herein. For example, in certain embodiments,peptides of the invention comprise a fragment of a sequence selectedfrom the group consisting of SEQ ID NOs: 1-543. The fragment can be,e.g., at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, or 44 amino acids in length. The fragment canalso be at least 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, or 66 amino acids long. In some embodiments,the fragment is no longer than 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,or 66 amino acids long. The fragment can be contiguous or can includeone or more deletions (e.g., a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9,10, or more amino acid residues). For instance, in one embodiment,peptides of the invention comprise a fragment of SEQ ID NO: 3. Suchfragments may comprise at least 10, 15, 20, 25, 30, or 35 contiguousamino acids from SEQ ID NO: 3. In some embodiments, the fragmentscomprise amino acids 1 to 35 of SEQ ID NO: 3. Thus, in one embodiment, apeptide of the invention comprises or consists of a sequence ofE-T-K-V-X₅-Y-X₇-Y-L-K-X₁₁-G-R-T-V-K-L-X₁₈-S-H-X₂₁-F-D-W-X₂₅-T-P-X₂₈-P-K-X₃₁-G-F-K-D(SEQ ID NO: 543), wherein X₅ is an amino acid selected from the groupconsisting of V or A, X₇ is an amino acid selected from the groupconsisting of G, I or H, X₁₁ is an amino acid selected from the groupconsisting of E, N, or Q, X₁₈ is an amino acid selected from the groupconsisting of D or N, X₂₁ is an amino acid selected from the groupconsisting of R, D, or N, X₂₅ is an amino acid selected from the groupconsisting of Q, D, or E, X₂₈ is an amino acid selected from the groupconsisting of E or N, and X₃₁ is an amino acid selected from the groupconsisting of L or V.

Peptides of the invention that comprise a fragment of a peptide sequencedescribed herein can further comprise an additional N-terminal peptidesequence, an additional C-terminal peptide sequence, or a combinationthereof. The additional N-terminal and C-terminal peptide sequences canbe as described above.

Peptides of the invention comprising an additional N-terminal orC-terminal peptide sequence can further comprise a linker connecting thepeptide (e.g., a peptide of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3,SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, orSEQ ID NO: 9, or a fragment thereof) with the additional N-terminal orC-terminal peptide sequence. The linker can be, e.g., a peptide spacer.Such spacer can consist of, for example, between about one and five(e.g., about three) amino acid residues, preferably uncharged aminoacids, e.g., aliphatic residues such as glycine or alanine. In oneembodiment, the spacer is a triplet glycine spacer. In anotherembodiment, the spacer is a triplet alanine spacer. In anotherembodiment, the spacer consists of five glycine amino acids. In yetanother embodiment, the spacer comprises both glycine and alanineresidues. Alternatively, the linker can be a chemical (i.e.,non-peptide) linker.

In certain embodiments, peptides of the invention are produced bysynthetic chemistry (i.e., a “synthetic peptide”). In other embodiments,peptides of the invention are produced biologically (i.e., by cellularmachinery, such as a ribosome, in cell expression systems or in vitrotranslation systems). In certain embodiments, peptides of the inventionare isolated. As used herein, an “isolated” peptide is a peptide thathas been produced either synthetically or biologically and thenpurified, at least partially, from the chemicals and/or cellularmachinery used to produce the peptide. In certain embodiments, anisolated peptide of the invention is substantially purified. The term“substantially purified,” as used herein, refers to a molecule, such asa peptide, that is substantially free of cellular material (proteins,lipids, carbohydrates, nucleic acids, etc.), culture medium, chemicalprecursors, chemicals used in synthesis of the peptide, or combinationsthereof. A peptide that is substantially purified has less than about40%, 30%, 25%, 20%, 15%, 10%, 5%, 2%, 1% or less of the cellularmaterial, culture medium, other polypeptides, chemical precursors,and/or chemicals used in synthesis of the peptide. Accordingly, asubstantially pure molecule, such as a peptide, can be at least about60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, by dry weight, themolecule of interest. An isolated peptide of the invention can be inwater, a buffer, or in a dry form awaiting reconstitution, e.g., as partof a kit. An isolated peptide of the present invention can be in theform of a pharmaceutically acceptable salt. Suitable acids and basesthat are capable of forming salts with the peptides of the presentinvention are well known to those of skill in the art, and includeinorganic and organic acids and bases.

In certain embodiments, peptides of the invention are affinity purified.For example, in certain embodiments, the peptides of the invention arepurified by means of their ability to bind to anti-Anaplasma antibodies(e.g., antibodies to MSP 2/p44 or OMP/p44 proteins and, optionally,other Anaplasma antigens) by contacting such antibodies with thepeptides of the invention such that peptide-antibody complexes are ableto form, washing the peptide-antibody complexes to remove impurities,and then eluting the peptides from the antibodies. The antibodies canbe, e.g., attached to a solid support. Methods of affinity purificationare well-known and routine to those skilled in the art.

In certain embodiments, peptides of the invention are modified. Thepeptides of the invention may be modified by a variety of techniques,such as by denaturation with heat and/or a detergent (e.g., SDS).Alternatively, peptides of the invention may be modified by associationwith one or more further moieties. The association can be covalent ornon-covalent, and can be, for example, via a terminal amino acid linker,such as lysine or cysteine, a chemical coupling agent, or a peptidebond. The additional moiety can be, for example, a ligand, a ligandreceptor, a fusion partner, a detectable label, an enzyme, or asubstrate that immobilizes the peptide.

Peptides of the invention can be conjugated to a ligand, such as biotin(e.g., via a cysteine or lysine residue), a lipid molecule (e.g., via acysteine residue), or a carrier protein (e.g., serum albumin,immunoglobulin Fc domain, keyhole limpet hemocyanin (KLH) via e.g., acysteine or lysine residue). Attachment to ligands, such as biotin, canbe useful for associating the peptide with ligand receptors, such asavidin, streptavidin, polymeric streptavidin (see, e.g., US 2010/0081125and US 2010/0267166, both of which are herein incorporated byreference), or neutravidin. Avidin, streptavidin, polymericstreptavidin, or neutravidin, in turn, can be linked to a signalingmoiety (e.g., an enzyme, such as horse radish peroxidase (HRP) oralkaline phosphatase (ALP) or β-galactosidase (β-GAL) or other moietythat can be visualized, such as a metallic nanomaterial such asnanoparticle, nanoplate, or nanoshell (e.g., colloidal gold), afluorescent moiety, or a quantum dot) or a solid substrate (e.g., anImmobilon™ or nitrocellulose membrane or Porex® membrane).Alternatively, the peptides of the invention can be fused or linked to aligand receptor, such as avidin, streptavidin, polymeric streptavidin,or neutravidin, thereby facilitating the association of the peptideswith the corresponding ligand, such as biotin and any moiety (e.g.,signaling moiety) or solid substrate attached thereto. Examples of otherligand-receptor pairs are well-known in the art and can similarly beused.

Peptides of the invention can be fused to a fusion partner (e.g., apeptide or other moiety) that can be used to improve purification, toenhance expression of the peptide in a host cell, to aid in detection,to stabilize the peptide, etc. Examples of suitable compounds for fusionpartners include carrier proteins (e.g., serum albumin, immunoglobulinFc domain, KLH), enzymes (e.g., horse radish peroxidase (HRP),beta-galactosidase, glutathione-S-transferase, alkaline phosphatase),maltose-binding protein (MBP) or a histidine tag, etc. The fusion can beachieved by means of, e.g., a peptide bond. For example, peptides of theinvention and fusion partners can be fusion proteins and can be directlyfused in-frame or can comprise a peptide linker, as discussed above inthe context of additional N-terminal and C-terminal peptide sequences.In certain embodiments, a population of peptides of the invention can belinked by a dendrimer, e.g., as in a MAPS structure.

In addition, peptides of the invention may be modified to include any ofa variety of known chemical groups or molecules. Such modificationsinclude, but are not limited to, glycosylation, acetylation, acylation,ADP-ribosylation, amidation, covalent attachment to polyethylene glycol(e.g., PEGylation), covalent attachment of flavin, covalent attachmentof a heme moiety, covalent attachment of a nucleotide or nucleotidederivative, covalent attachment of a lipid or lipid derivative, covalentattachment of phosphatidylinositol, cross-linking, cyclization,disulfide bond formation, demethylation, formation of covalentcross-links, formation of cystine, formation of pyroglutamate,formylation, gamma carboxylation, glycosylation, GPI anchor formation,hydroxylation, iodination, methylation, myristoylation, oxidation,proteolytic processing, phosphorylation, prenylation, racemization,selenoylation, sulfation, ubiquitination, modifications with fattyacids, transfer-RNA mediated addition of amino acids to proteins such asarginylation, etc. Analogues of an amino acid (including unnatural aminoacids) and peptides with substituted linkages are also included.Peptides of the invention that consist of any of the sequences discussedherein may be modified by any of the discussed modifications. Suchpeptides still “consist of” the amino acids.

Modifications as set forth above are well-known to those of skill in theart and have been described in great detail in the scientificliterature. Several particularly common modifications, glycosylation,lipid attachment, sulfation, gamma-carboxylation of glutamic acidresidues, hydroxylation and ADP-ribosylation, for instance, aredescribed in many basic texts, such as Proteins-Structure and MolecularProperties, 2nd ed., T. E. Creighton, W. H. Freeman and Company, NewYork (1993). Many detailed reviews are available on this subject, suchas by Wold, F., Posttranslational Covalent Modification of Proteins, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al.(1990) Meth. Enzymol. 182:626-646 and Rattan et al. (1992) Ann. N.Y.Acad. Sci. 663:48-62.

In certain embodiments, peptides of the invention are attached to orimmobilized on a substrate, such as a solid or semi-solid support. Theattachment can be covalent or non-covalent, and can be facilitated by amoiety associated with the peptide that enables covalent or non-covalentbinding, such as a moiety that has a high affinity to a componentattached to the carrier, support or surface. For example, the peptidecan be associated with a ligand, such as biotin, and the componentassociated with the surface can be a corresponding ligand receptor, suchas avidin. In some embodiments, the peptide can be associated with afusion partner, e.g., bovine serum albumin (BSA), which facilitates theattachment of the peptide to a substrate. In other embodiments, thepeptides of the invention are attached to or immobilized on a substratevia a metallic nanolayer. In one embodiment, the metallic nanolayer iscomprised of cadmium, zinc, mercury, or a noble metal, such as gold,silver, copper, and platinum. The peptide or population of peptides canbe attached to or immobilized on the substrate either prior to or afterthe addition of a sample containing antibody during an immunoassay.

In certain embodiments, the substrate is a bead or plurality of beads,such as a colloidal particle (e.g., a colloidal nanoparticle made fromgold, silver, platinum, copper, cadmium, metal composites, other softmetals, core-shell structure particles, or hollow gold nanospheres) orother type of particle (e.g., a magnetic bead or a particle ornanoparticle comprising silica, latex, polystyrene, polycarbonate,polyacrylate, PVDF, or PMMA). Such particles can comprise a label (e.g.,a colorimetric, chemiluminescent, quantum dot or fluorescent label) andcan be useful for visualizing the location of the peptides duringimmunoassays. In certain embodiments, a terminal cysteine of a peptideof the invention is used to bind the peptide directly to a metallicnanomaterial or nanostructure.

The metallic nanomaterials or nanostructures used in some embodiments ofthe invention can be made from gold, silver, platinum, palladium,copper, cadmium, metal composites, or other soft metals. In someembodiments, the metallic nanomaterials or nanostructures, including thecomposite nanostructures, have a geometry selected from sphericalnanoparticles, pyramidal nanoparticles, hexagonal nanoparticles,nanoshells, nanoplates, nanotubes, nanowires, and combinations thereof.Examples of metallic nanoshells include gold hollow spheres, gold-coatedsilica nanoshells, and silica-coated gold shells. Nanoplates havelateral dimensions (e.g. edge lengths) that are greater than theirthickness. Nanoplates include nanodisks, nanopolygons, nanohexagons,nanocubes, nanorings, nanostars, and nanoprisms. In some embodiments,the metallic nanostructures have other shapes or irregular shapes. Incertain embodiments, the size and shape of the metallic nanostructuresare not uniform—i.e. the metallic nanostructures are a heterogeneousmixture of different shapes and sizes of nanostructures.

For spherical nanoparticles, suitable diameter ranges include from about5 nm to about 200 nm, from about 10 nm to about 100 nm, and from about20 nm to about 60 nm. For nanoplates, edge lengths may be from about 10nm to about 800 nm, from about 20 nm to about 500 nm, from about to 50nm to about 200 nm, from about 30 nm to about 100 nm, or from about 10nm to about 300 nm. The thickness of the nanoplates can range from about1 to about 100 nm, from about 5 nm to about 80 nm, from about 10 nm toabout 50 nm, or from about 5 nm to about 20 nm.

In some embodiments, the nanoplates have an aspect ratio greater than 2.The aspect ratio is the ratio of the edge length to the thickness.Preferably, the nanoplates have an aspect ratio from about 2 to about25, from about 3 to about 20, from about 5 to about 10, from about 2 toabout 15, or from about 10 to about 30.

In certain embodiments, the substrate is a dot blot or a flow path in alateral flow immunoassay device. For example, the peptides can beattached or immobilized on a porous membrane, such as a PVDF membrane(e.g., an Immobilon™ membrane), a nitrocellulose membrane, polyethylenemembrane, nylon membrane, or a similar type of membrane.

In certain embodiments, the substrate is a flow path in an analytical orcentrifugal rotor. In other embodiments, the substrate is a tube or awell, such as a well in a plate (e.g., a microtiter plate) suitable foruse in an ELISA assay. Such substrates can comprise glass,cellulose-based materials, thermoplastic polymers, such as polyethylene,polypropylene, or polyester, sintered structures composed of particulatematerials (e.g., glass or various thermoplastic polymers), or castmembrane film composed of nitrocellulose, nylon, polysulfone, or thelike. A substrate can be sintered, fine particles of polyethylene,commonly known as porous polyethylene, for example, 0.2-15 micron porouspolyethylene from Chromex Corporation (Albuquerque, N. Mex.). All ofthese substrate materials can be used in suitable shapes, such as films,sheets, or plates, or they may be coated onto or bonded or laminated toappropriate inert carriers, such as paper, glass, plastic films, orfabrics. Suitable methods for immobilizing peptides on solid phasesinclude ionic, hydrophobic, covalent interactions and the like.

Accordingly, in another aspect, the invention provides devices. Incertain embodiments, the devices are useful for performing animmunoassay. For example, in certain embodiments, the device is alateral flow immunoassay device. An exemplary lateral flow immunoassaydevice comprising peptides of the invention is described in Example 2.In certain embodiments, the lateral flow immunoassay device comprises apopulation of peptides, wherein each peptide in the population comprisesa sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, orSEQ ID NO: 9. In some embodiments, the device is a slide comprised of aplurality of beads to which a peptide or population of peptides isattached. An example of such a device comprising peptides of theinvention suitable for use, for example, in an indirect fluorescentantibody assay is described in Example 3. In other embodiments, thedevice is an analytical or centrifugal rotor. In other embodiments, thedevice is a dot blot, slot blot, or Western blot. In other embodiments,the device is a tube or a well, e.g., in a plate suitable for an ELISAassay. An exemplary device comprising peptides of the invention for usein an ELISA assay is described in Example 1. In still other embodiments,the device is an electrochemical sensor, an optical sensor, or anopto-electronic sensor.

In certain embodiments, the device comprises a peptide or population ofpeptides of the invention. In other embodiments, the device comprises amixture of different peptides of the invention. For example, in certainembodiments, the device comprises two, three, four, or more differentpeptides of the invention. In certain embodiments, the peptide or eachpeptide in the population comprises a sequence of SEQ ID NO: 1, SEQ IDNO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ IDNO: 7, SEQ ID NO: 8, or SEQ ID NO: 9 or a fragment thereof. In otherembodiments, the peptide or each peptide in the population comprises asequence of SEQ ID NO: 3, SEQ ID NO: 4, or a fragment thereof. Incertain embodiments, the population of peptides are attached to orimmobilized upon the device optionally through a metallic nanolayer. Thedevices may be used to detect the presence of antibodies to Anaplasmaantigens from multiple species (e.g., A. phagocytophilum, A. platys, andA. marginale) in a sample simultaneously. In one embodiment, the devicecomprises a population of isolated peptides comprising three or moredifferent peptides, wherein each peptide in the population comprises asequence of SEQ ID NO: 3. In another embodiment, the device comprises apopulation of isolated peptides comprising three or more differentpeptides, wherein each peptide in the population comprises a sequence ofSEQ ID NO: 4. In another embodiment, the device comprises a populationof isolated peptides comprising three or more different peptides,wherein each peptide in the population comprises a sequence of SEQ IDNO: 1. In still another embodiment, the device comprises a population ofisolated peptides comprising three or more different peptides, whereineach peptide in the population comprises a sequence of SEQ ID NO: 8. Inother embodiments, the device comprises a population of isolatedpeptides comprising three or more different peptides, wherein eachpeptide in the population comprises a sequence of SEQ ID NO: 2, SEQ IDNO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 9.

In another aspect, the invention provides compositions comprising one ormore peptides of the invention. For example, in certain embodiments, theinvention provides a composition comprising a peptide comprising asequence of SEQ ID NO: 3, or populations thereof. In certainembodiments, the composition comprises a population of 2, 3, 4, 5, 6, 7,8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250,300, 400, 500, or more peptides (e.g., all possible peptides defined bySEQ ID NO: 3). Thus, the present invention provides a population ofisolated peptides comprising three or more different peptides, whereineach peptide in the population comprises a sequence of SEQ ID NO: 3. Incertain embodiments, the peptides in the population or mixture comprisean N-terminal and/or C-terminal addition, and/or are modified (e.g., byassociation with one or more further moieties), as described herein. Incertain embodiments, the peptides comprise the same N-terminal and/orC-terminal additions. In other embodiments, the peptides comprisedifferent N-terminal and/or C-terminal additions.

In some embodiments, the invention provides a composition comprising apeptide comprising a sequence of SEQ ID NO: 4, or populations thereof.In certain embodiments, the composition comprises a population of 2, 3,4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150,200, 250, 300, 400, 500, or more peptides (e.g., all possible peptidesdefined by SEQ ID NO: 4). Thus, the present invention provides apopulation of isolated peptides comprising three or more differentpeptides, wherein each peptide in the population comprises a sequence ofSEQ ID NO: 4. In certain embodiments, the peptides in the population ormixture comprise an N-terminal and/or C-terminal addition, and/or aremodified (e.g., by association with one or more further moieties), asdescribed herein. In certain embodiments, the peptides comprise the sameN-terminal and/or C-terminal additions. In other embodiments, thepeptides comprise different N-terminal and/or C-terminal additions.

In still other embodiments, the invention provides a compositioncomprising a peptide comprising a sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,SEQ ID NO: 543, or populations thereof. In certain embodiments, thecomposition comprises a population of 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500,or more peptides (e.g., all possible peptides defined by SEQ ID NO: 1,SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,SEQ ID NO: 543). Thus, the invention provides a population of isolatedpeptides comprising three or more different peptides, wherein eachpeptide in the population comprises a sequence of SEQ ID NO: 1. Inanother embodiment, the invention provides a population of isolatedpeptides comprising three or more different peptides, wherein eachpeptide in the population comprises a sequence of SEQ ID NO: 2. In otherembodiments, the invention provides a population of isolated peptidescomprising three or more different peptides, wherein each peptide in thepopulation comprises a sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ IDNO: 8, SEQ ID NO: 9, or SEQ ID NO: 543. The peptides in the populationor mixture may comprise an N-terminal and/or C-terminal addition, and/orbe modified (e.g., by association with one or more further moieties), asdescribed herein.

In some embodiments, the composition comprises a population of isolatedpeptides, said population comprising three or more different peptides,wherein each peptide in the population comprises a sequence, or afragment thereof, of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, or 9.

In some embodiments, the composition comprises at least two differentpopulations of peptides described herein. In certain embodiments, atleast one of the peptide populations is defined by SEQ ID NO: 3 (i.e.,comprising three or more different peptides, wherein each peptide in thepopulation comprises a sequence, or a fragment thereof, of SEQ ID NO:3).

In certain embodiments, the composition further comprises a secondpopulation of isolated peptides. In some embodiments, the second peptidepopulation is defined by SEQ ID NO: 7. In some other embodiments, eachpeptide in the second peptide population comprises the sequence, or afragment thereof, of SEQ ID NO: 6.

In some embodiments, the composition further comprises a thirdpopulation of isolated peptides that is different from the first andsecond peptide populations. In certain embodiments, each peptide in thethird peptide population comprises the sequence, or a fragment thereof,of SEQ ID NO: 6.

In a particular embodiment, the composition comprises three differentpopulations of peptides, a first peptide populations which is defined bySEQ ID NO: 3, a second peptide population which is defined by SEQ ID NO:7, and a third peptide population in which each peptide comprises thesequence, or a fragment thereof, of SEQ ID NO: 6.

In certain embodiments, the compositions comprise one or more peptides(or one or more populations of peptides) of the invention and one ormore additional peptides, such as an Anaplasma peptide or antigen, apeptide or antigen from one or more Ehrlichia species, and/or a peptideor antigen from one or more Borrelia species. The Anaplasma peptide orantigen can be any Anaplasma surface peptide or antigen, or any peptideor antigen described herein. For instance, in certain embodiments, thecompositions comprise a mixture of peptides, wherein each peptide has asequence of SEQ ID NO: 3, SEQ ID NO: 6, or SEQ ID NO: 7. In otherembodiments, the compositions comprise a mixture of peptides, whereineach peptide has a sequence of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO:6.

Suitable Ehrlichia peptides that can be mixed with the Anaplasmapeptides of the invention include any Ehrlichia surface peptide orantigen including, but not limited to, OMP-1, p38, p43, p120, p140,p153, p156, p200, gp19, gp36, gp47, gp200, or HGE-3 protein, or anyfragment or epitope thereof. Other suitable Ehrlichia peptides includepeptides described in U.S. application Ser. No. 14/052,296 and U.S. Pat.No. 8,828,675, the contents of each of which are hereby incorporated byreference in their entireties. Suitable Borrelia peptides that can bemixed with the Anaplasma peptides of the invention include any Borreliasurface peptide or antigen including, but not limited to, OspA, OspB,DbpA, flagella-associated proteins FlaA (p37) and FlaB (p41), OspC (25kd), BBK32, BmpA (p39), p21, p39, p66 or p83 protein, or any fragment orepitope thereof. Other suitable Borrelia peptides include peptidesdescribed in U.S. Pat. Nos. 8,568,989 and 8,758,772, the contents ofeach of which are hereby incorporated by reference in their entireties.The combination may comprise a cocktail (a simple mixture) of individualpeptides or polypeptides, it may be in the form of a fusion peptide orpolypeptide (e.g., a multimeric peptide), or the peptides may be linkedby a dendrimer (e.g., as in a MAPS structure) optionally through alinking residue (e.g. lysine or cysteine residue). For instance, incertain embodiments, a composition comprises one or more peptides of theinvention (e.g., a peptide having a sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7,SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 543) and one or more antigenicEhrlichia peptides and/or one or more antigenic Borrelia peptides.

When a composition comprises multiple peptides or peptide populations,the ratio among the various peptides or peptide populations can bevaried in order to tailor the composition's performance, e.g., in termsof sensitivity and selectivity. For example, in a composition comprisingtwo peptide populations, the molar ratio of the two peptide populationscan vary anywhere between 20:1 to 1:20, e.g., 20:1, 10:1, 5:1, 3:1, 2:1,1:1, 1:2, 1:3, 1:5, 1:10, or 1:20. Or, the percentage of weight ratiocan vary between 95:5 to 5:95, e.g., 95:5, 90:10, 80:20, 70:30, 60:40,50:50, 40:60, 30:70, 20:80, 10:90, or 5:95. In a composition comprisingthree or more peptide populations, the percentage of moles or weight ofeach peptide population can vary from 1% to 98% of the total moles orweight of all three peptide populations, e.g., 1%, 2%, 5%, 10%, 15%,20%, 25%, 30%, 33%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, etc. In acertain embodiment, the composition comprises three peptide populations,APL-ID1 (defined by SEQ ID NO: 3), APL-ID5.1 (each peptide comprisingSEQ ID NO: 6), and APL-ID6 (defined by SEQ ID NO: 7) in a weight ratioof 50:25:25. In another embodiment, the composition comprises threepeptide populations, APL-ID1 (defined by SEQ ID NO: 3), APL-ID5.1 (eachpeptide comprising SEQ ID NO: 6), and APL-ID6 (defined by SEQ ID NO: 7),wherein each peptide population constitutes a third of the compositionby weight.

A peptide of the invention may be fused at its N-terminus or C-terminusto another suitable peptide. Two or more copies of a peptide of theinvention may be joined to one another, alone or in combination with oneor more additional peptides. Combinations of fused and unfused peptidesor polypeptides can be used. In one embodiment, the additionalpeptide(s) contain B-cell and/or T-cell epitopes from an Anaplasmapeptide or antigen, a peptide or antigen from an infectious Anaplasmaspecies, or a peptide or antigen from a causative agent of anaplasmosis.

In another aspect, the invention provides nucleic acids comprising asequence encoding a peptide of the invention. Nucleic acids of theinvention contain less than an entire microbial genome and can besingle- or double-stranded. A nucleic acid can be RNA, DNA, cDNA,genomic DNA, chemically synthesized RNA or DNA or combinations thereof.The nucleic acids can be purified free of other components, such asproteins, lipids and other polynucleotides. For example, the nucleicacids can be 50%, 75%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% purified.The nucleic acids of the invention encode the peptides described herein.In certain embodiments, the nucleic acids encode a peptide having thesequence of SEQ ID NOs: 1-543, or combinations thereof. Nucleic acids ofthe invention can comprise other nucleotide sequences, such as sequencescoding for linkers, signal sequences, TMR stop transfer sequences,transmembrane domains, or ligands useful in protein purification such asglutathione-S-transferase, histidine tag, MBP tag and staphylococcalprotein A.

Nucleic acids of the invention can be isolated. An “isolated” nucleicacid is one that is not immediately contiguous with one or both of the5′ and 3′ flanking genomic sequences with which it is naturallyassociated. An isolated nucleic acid can be, e.g., a recombinant DNAmolecule of any length, provided that the nucleic acid sequencesnaturally found immediately flanking the recombinant DNA molecule in anaturally-occurring genome is removed or absent. Isolated nucleic acidsalso include non-naturally occurring nucleic acid molecules. Nucleicacids of the invention can also comprise fragments that encodeimmunogenic peptides. Nucleic acids of the invention can encodefull-length polypeptides, peptide fragments, and variant or fusionpeptides.

Nucleic acids of the invention can be isolated, at least in part, fromnucleic acid sequences present in, for example, a biological sample,such as blood, serum, saliva, or tissue from an infected individual.Nucleic acids can also be synthesized in the laboratory, for example,using an automatic synthesizer. An amplification method such as PCR canbe used to amplify nucleic acids, at least in part, from either genomicDNA or cDNA encoding the polypeptides.

Nucleic acids of the invention can comprise coding sequences fornaturally occurring polypeptides or can encode altered sequences that donot occur in nature. If desired, nucleic acids can be cloned into anexpression vector comprising expression control elements, including forexample, origins of replication, promoters, enhancers, or otherregulatory elements that drive expression of the polynucleotides of theinvention in host cells. An expression vector can be, for example, aplasmid, such as pBR322, pUC, or ColE1, or an adenovirus vector, such asan adenovirus Type 2 vector or Type 5 vector. Optionally, other vectorscan be used, including but not limited to Sindbis virus, simian virus40, alphavirus vectors, poxvirus vectors, and cytomegalovirus andretroviral vectors, such as murine sarcoma virus, mouse mammary tumorvirus, Moloney murine leukemia virus, and Rous sarcoma virus.Minichromosomes such as MC and MC1, bacteriophages, phagemids, yeastartificial chromosomes, bacterial artificial chromosomes, virusparticles, virus-like particles, cosmids (plasmids into which phagelambda cos sites have been inserted) and replicons (genetic elementsthat are capable of replication under their own control in a cell) canalso be used.

Methods for preparing polynucleotides operably linked to an expressioncontrol sequence and expressing them in a host cell are well-known inthe art. See, e.g., U.S. Pat. No. 4,366,246. A nucleic acid of theinvention is operably linked when it is positioned adjacent to or closeto one or more expression control elements, which direct transcriptionand/or translation of the polynucleotide.

Thus, for example, a peptide of the invention can be producedrecombinantly following conventional genetic engineering techniques. Toproduce a recombinant peptide of the invention, a nucleic acid encodingthe peptide is inserted into a suitable expression system. Generally, arecombinant molecule or vector is constructed in which thepolynucleotide sequence encoding the selected peptide is operably linkedto an expression control sequence permitting expression of the peptide.Numerous types of appropriate expression vectors are known in the art,including, e.g., vectors containing bacterial, viral, yeast, fungal,insect or mammalian expression systems. Methods for obtaining and usingsuch expression vectors are well-known. For guidance in this and othermolecular biology techniques used for compositions or methods of theinvention, see, e.g., Sambrook et al., Molecular Cloning, A LaboratoryManual, current edition, Cold Spring Harbor Laboratory, New York; Milleret al., Genetic Engineering, 8:277-298 (Plenum Press, current edition),Wu et al., Methods in Gene Biotechnology (CRC Press, New York, N.Y.,current edition), Recombinant Gene Expression Protocols, in Methods inMolecular Biology, Vol. 62, (Tuan, ed., Humana Press, Totowa, N.J.,current edition), and Current Protocols in Molecular Biology, (Ausubelet al., Eds.,) John Wiley & Sons, NY (current edition), and referencescited therein.

Accordingly, the invention also provides vectors comprising nucleicacids of the invention, and host cells comprising such vectors. Incertain embodiments, the vector is a shuttle vector. In otherembodiments, the vector is an expression vector (e.g., a bacterial oreukaryotic expression vector). In certain embodiments, the host cell isa bacterial cell. In other embodiments, the host cell is a eukaryoticcell.

Suitable host cells or cell lines for expression of the recombinantnucleic acids or vectors of the invention include bacterial cells. Forexample, various strains of E. coli (e.g., HB101, MC1061) are well-knownas host cells in the field of biotechnology. Various strains of B.subtilis, Pseudomonas, Streptomyces, and other bacilli and the like canalso be employed to express the nucleic acids or vectors of theinvention. Alternatively, a peptide of the invention can be expressed inyeast, insect, mammalian, or other cell types, using conventionalprocedures. Cell-free in vitro synthesis and/or enzyme-mediatedsynthetic machineries may also be used.

The present invention also provides a method for producing a recombinantpeptide or polypeptide, which involves transfecting or transforming,e.g., by conventional means such as electroporation, a host cell with atleast one expression vector containing a polynucleotide of the inventionunder the control of an expression control sequence (e.g., atranscriptional regulatory sequence). The transfected or transformedhost cell is then cultured under conditions that allow expression of thepeptide or polypeptide. The expressed peptide or polypeptide isrecovered, isolated, and optionally purified from the cell (or from theculture medium, if expressed extracellularly) by appropriate means knownto one of skill in the art, including liquid chromatography such asnormal or reversed phase, using HPLC, FPLC and the like, affinitychromatography, such as with inorganic ligands or monoclonal antibodies,size exclusion chromatography, immobilized metal chelate chromatography,gel electrophoresis, and the like. One of skill in the art may selectthe most appropriate isolation and purification techniques withoutdeparting from the scope of this invention. One skilled in the art candetermine the purity of the peptide or polypeptide by using standardmethods including, e.g., polyacrylamide gel electrophoresis (e.g.,SDS-PAGE), capillary electrophoresis, column chromatography (e.g., highperformance liquid chromatography (HPLC)), amino-terminal amino acidanalysis, and quantitative amino acid analysis.

Methods

In another aspect, the invention provides methods of detecting in asample an antibody to an epitope of an Anaplasma antigen. In oneembodiment, the method comprises contacting a sample with a peptide ofthe invention, and detecting formation of an antibody-peptide complexcomprising said peptide, wherein formation of said complex is indicativeof the presence of an antibody to an epitope of an Anaplasma antigen insaid sample. In some embodiments, the Anaplasma antigen is from aninfectious Anaplasma species, such as Anaplasma phagocytophilum,Anaplasma platys, or Anaplasma marginale. Other species of Anaplasmawhich have been implicated in anaplasmosis can also be detected usingthe methods of the invention, provided they induce antibodies which canreact specifically with a peptide of the invention. Thus, it is to beunderstood that the term “pathogenic Anaplasma,” as used herein, refersto any such Anaplasma species that causes anaplasmosis in a human or ananimal. In particular embodiments, the methods provide detection ofantibodies to Anaplasma antigens from multiple species in a samplesimultaneously.

In certain embodiments, the method of detecting in a sample an antibodyto an epitope of an Anaplasma antigen comprises contacting the samplewith a population of two, three, four, or more (e.g., 5, 6, 7, 8, 9, 10,15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400,500, or more) different peptides of the invention, and detectingformation of an antibody-peptide complex comprising said one or morepeptides in the population, wherein formation of said complex isindicative of an antibody to an epitope of an Anaplasma antigen beingpresent in said sample. For instance, in one particular embodiment, themethod comprises contacting the sample with a population of two or moredifferent isolated peptides, wherein each isolated peptide comprises asequence of SEQ ID NO: 3. In another particular embodiment, the methodcomprises contacting the sample with a population of two or moredifferent isolated peptides, wherein each isolated peptide comprises asequence of SEQ ID NO: 4. In still another embodiment, the methodcomprises contacting the sample with a population of two or moredifferent isolated peptides, wherein each isolated peptide comprises asequence of SEQ ID NO: 1. In some embodiments, the method comprisescontacting the sample with a population of two or more differentisolated peptides, wherein each isolated peptide comprises a sequence ofSEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8,SEQ ID NO: 9, or SEQ ID NO: 543. In certain embodiments, the methodcomprises contacting the sample with a mixture of one or more peptidesof the invention and one or more other peptides (e.g., an Ehrlichiapeptide, or antigenic fragment or epitope thereof and/or a Borreliapeptide or antigenic fragment or epitope thereof).

In certain embodiments, the peptide or each peptide in the population isan isolated (e.g., synthetic and/or purified) peptide. In someembodiments, the peptide or population of peptides is attached to orimmobilized upon a solid support. In such embodiments, the solid supportis a bead or plurality of beads (e.g., a metallic nanomaterial such asnanoparticle, nanoplate, or nanoshell, a nanoparticle, a latex bead,etc.), a flow path in a lateral flow immunoassay device (e.g., a porousmembrane), a flow path in an analytical or centrifugal rotor, a blot(Western blot, dot blot, or slot blot), a tube or a well (e.g., in aplate suitable for an ELISA assay), or a sensor (e.g., anelectrochemical, optical, or opto-electronic sensor). In someembodiments, the peptide or population of peptides is attached to orimmobilized upon a solid support through a metallic nanolayer that, insome embodiments, may be comprised of cadmium, zinc, mercury, or a noblemetal (e.g., gold, silver, copper, and platinum). In some embodiments,the peptides or populations of peptides of the invention are immobilizedon a composite nanolayer (for example comprising silver and gold) orgold-coated silver nanolayers.

There are a number of different conventional assays for detectingformation of an antibody-peptide complex comprising a peptide of theinvention. For example, in some embodiments, the detecting stepcomprises performing an ELISA or immunofluorescence assay. In otherembodiments, the detecting step comprises performing a lateral flowimmunoassay. In other embodiments, the detecting step comprisesperforming an agglutination assay (e.g., a hemagglutination orparticle/bead agglutination assay). In still other embodiments, thedetecting step comprises spinning the sample in an analytical orcentrifugal rotor. In some embodiments, the detecting step comprisesperforming a Western blot, slot blot, or dot blot. In certainembodiments, the detecting step comprises performing a wavelength shiftassay. Such wavelength shift assays may entail measuring or determininga change in the surface plasmon resonance or localized surface plasmonresonance wavelength resulting from binding of antibodies to peptidesattached to metallic nanolayers or metallicnanoparticles/nanoshells/nanoplates. In other embodiments, the detectingstep comprises performing an Indirect Fluorescent Antibody test. In someembodiments, the Indirect Fluorescent Antibody test comprises reactingsamples suspected of containing antibodies against Anaplasma antigenswith beads (e.g. latex beads) coated with the peptides of the invention,which are further immobilized on a glass slide, and subsequentlyreacting the slide with fluorescently labeled anti-dog IgG or IgMantibodies to detect bound anti-Anaplasma antibodies. An example of anIndirect Fluorescent Antibody test is described in Example 3. In stillother embodiments, the detecting step comprises analyzing the samplewith an electrochemical, optical, or opto-electronic sensor. Thesedifferent assays are described herein and/or are well-known to thoseskilled in the art.

In one embodiment, the method involves detecting the presence ofnaturally occurring antibodies against one or more Anaplasma antigens(e.g., the antigen of a pathogenic Anaplasma, such as A.phagocytophilum, A. platys, or A. marginale) which are produced by theinfected subject's immune system in its biological fluids or tissues,and which are capable of binding specifically to a peptide of theinvention or combinations of a peptide of the invention and, optionally,one or more suitable additional antigenic polypeptides or peptides.

Suitable immunoassay methods typically include: receiving or obtaining(e.g., from a patient) a sample of body fluid or tissue likely tocontain antibodies; contacting (e.g., incubating or reacting) a sampleto be assayed with a peptide or population of peptides of the invention,under conditions effective for the formation of a specificpeptide-antibody complex (e.g., for specific binding of the peptide tothe antibody); and assaying the contacted (reacted) sample for thepresence of an antibody-peptide reaction (e.g., determining the amountof an antibody-peptide complex). The presence of an elevated amount ofthe antibody-peptide complex indicates that the subject was exposed toand infected with an infectious Anaplasma species. A peptide, includinga modified form thereof, which “binds specifically” to (e.g., “isspecific for” or binds “preferentially” to) an antibody against anAnaplasma antigen interacts with the antibody, or forms or undergoes aphysical association with it, in an amount and for a sufficient time toallow detection of the antibody. By “specifically” or “preferentially,”it is meant that the peptide has a higher affinity (e.g., a higherdegree of selectivity) for such an antibody than for other antibodies ina sample. For example, the peptide can have an affinity for the antibodyof at least about 1.5-fold, 2-fold, 2.5-fold, 3-fold, or higher than forother antibodies in the sample. Such affinity or degree of specificitycan be determined by a variety of routine procedures, including, e.g.,competitive binding studies. In an ELISA assay, a positive response isdefined as a value 2 or 3 standard deviations greater than the meanvalue of a group of healthy controls. In some embodiments, a second tierassay is required to provide an unequivocal serodiagnosis ofanaplasmosis.

Phrases such as “sample containing an antibody” or “detecting anantibody in a sample” are not meant to exclude samples or determinations(e.g., detection attempts) where no antibody is contained or detected.In a general sense, this invention involves assays to determine whetheran antibody produced in response to infection with an infectiousAnaplasma species is present in a sample, irrespective of whether or notit is detected.

Conditions for reacting peptides and antibodies so that they reactspecifically are well-known to those of skill in the art. See, e.g.,Current Protocols in Immunology (Coligan et al., editors, John Wiley &Sons, Inc).

The methods of the invention comprise receiving or obtaining a sample ofbody fluid or tissue likely to contain antibodies from a subject. Theantibodies can be, e.g., of IgG, IgE, IgD, IgM, or IgA type. Generally,IgM and/or IgA antibodies are detected, e.g., for detection at earlystages of infection. IgG antibodies can be detected when some of theadditional peptides discussed above are used in the method (e.g.,peptides for the detection of flagellum proteins). The sample ispreferably easy to obtain and may be whole blood, plasma, or serumderived from a venous blood sample or even from a finger prick. Tissuefrom other body parts or other bodily fluids, such as cerebro-spinalfluid (CSF), saliva, gastric secretions, mucus, urine, etc., are knownto contain antibodies and may be used as a source of the sample. Thesample may also be a tissue extract or a cell lysate.

Once the peptide or population of peptides of the invention and sampleantibody are permitted to react in a suitable medium, an assay isperformed to determine the presence or absence of an antibody-peptidereaction. Among the many types of suitable assays, which will be evidentto a skilled worker, are immunoprecipitation and agglutination assays.

In certain embodiments of the invention, the assay comprises:immobilizing the antibody(s) in the sample; adding a peptide orpopulation of peptides of the invention; and detecting the degree ofantibody bound to the peptide or peptides, e.g., by the peptide beinglabeled or by adding a labeled substance, such as a labeled bindingpartner (e.g., streptavidin-HRP or streptavidin-colloidal gold complex)or a labeled antibody which specifically recognizes the peptide orpeptides. See, e.g., FIG. 2. In other embodiments, the assay comprises:immobilizing a peptide or population of peptides of the invention;adding the sample containing antibodies; and detecting the amount ofantibody bound to the peptide or peptides, e.g., by adding anotherpeptide or population of peptides of the invention conjugated, directlyor indirectly, to a label (e.g., metallic nanomaterial such asnanoparticle, nanoplate, or nanoshell, fluorescent label, enzyme (e.g.,horseradish peroxidase or alkaline phosphatase)) or by adding a labeledsubstance, such as a binding partner or a labeled antibody whichspecifically recognizes the sample antibodies (e.g., anti-human IgGantibodies, anti-human IgM antibodies, anti-dog IgG antibodies, anti-dogIgM antibodies, anti-cat IgG antibodies, anti-cat IgM antibodies,protein A, protein G, protein A/G fusion proteins, protein L, orcombinations thereof, etc.). See, e.g., FIGS. 1, 3, and 4.

In other embodiments, the assay comprises: immobilizing a peptide orpopulation of peptides of the invention; adding the sample containingantibodies; and detecting the amount of antibody bound to the peptide orpeptides, e.g., by adding a first binding partner which specificallyrecognizes the sample antibodies (e.g., anti-human IgG antibodies,anti-human IgM antibodies, anti-dog IgG antibodies, anti-dog IgMantibodies, anti-cat IgG antibodies, anti-cat IgM antibodies, protein A,protein G, protein A/G fusion proteins, protein L, etc.), and furtheradding a second binding partner (e.g., protein A, protein G, protein A/Gfusion proteins, protein L, etc.), wherein the second binding partner islabeled and recognizes said first binding partner. In still otherembodiments, the assay comprises: reacting the peptide or population ofpeptides and the sample containing antibodies without any of thereactants being immobilized, and then detecting the amount of complexesof antibody and peptide or peptides, e.g., by the peptide being labeledor by adding a labeled substance, such as a labeled binding partner(e.g., streptavidin-HRP or streptavidin-colloidal gold complex) or alabeled antibody which specifically recognizes the peptide.

Immobilization of a peptide or population of peptides of the inventioncan be either covalent or non-covalent, and the non-covalentimmobilization can be non-specific (e.g., non-specific binding to apolystyrene surface in, e.g., a microtiter well). Specific orsemi-specific binding to a solid or semi-solid carrier, support orsurface, can be achieved by the peptide having, associated with it, amoiety which enables its covalent or non-covalent binding to the solidor semi-solid carrier, support or surface. For example, the moiety canhave affinity to a component attached to the carrier, support orsurface. In this case, the moiety may be, e.g., a biotin or biotinylgroup or an analogue thereof bound to an amino acid group of thepeptide, such as 6-aminohexanoic acid, and the component is then avidin,streptavidin, neutravidin, or an analogue thereof. An alternative is asituation in which the moiety is a histidine tag (e.g. six consecutivehistidine amino acids) and the carrier comprises a Nitrilotriacetic Acid(NTA) derivative charged with Ni++ or Co++ ions. In certain embodiments,the moiety is a fusion partner, e.g., BSA. In exemplary embodiments,peptides of the invention may be conjugated to BSA via N-terminal and/orC-terminal residues of the peptides. In one embodiment, one, two, three,four, five, 10, 15, 20, 25, 30 or more peptides of the invention may besubstituted into, e.g., conjugated with BSA. As would be understood byone skilled in the art, substitution levels may impact the sensitivityof the assay. Lower concentrations of highly substituted BSA are neededto achieve sensitivity offered by high concentrations of BSA-peptidecontaining fewer molecules of peptide. In certain other embodiments, thefusion partner may be MAPS. In certain exemplary embodiments, MAPS mayconsist of 4, 8, or more asymmetric branches.

Suitable carriers, supports, and surfaces include, but are not limitedto, metallic nanolayers, beads (e.g., magnetic beads, colloidalparticles or metallic nanomaterials, such as metallic nanoparticles,nanoplates, or nanoshells, such as colloidal gold, or particles ornanoparticles comprising silica, latex, polystyrene, polycarbonate, orPDVF), latex or co-polymers such as styrene-divinyl benzene,hydroxylated styrene-divinyl benzene, polystyrene, carboxylatedpolystyrene, beads of carbon black, non-activated or polystyrene orpolyvinyl chloride activated glass, epoxy-activated porous magneticglass, gelatin or polysaccharide particles or other protein particles,red blood cells, mono- or polyclonal antibodies or Fab fragments of suchantibodies.

The protocols for immunoassays using antigens for detection of specificantibodies are well known in art. For example, a conventional sandwichassay can be used, or a conventional competitive assay format can beused. For a discussion of some suitable types of assays, see CurrentProtocols in Immunology (supra). In certain embodiments, a peptide orpopulation of peptides of the invention is immobilized on a solid orsemi-solid surface or carrier by means of covalent or non-covalentbinding, either prior to or after the addition of the sample containingantibody.

Devices for performing specific binding assays, especially immunoassays,are known and can be readily adapted for use in the present methods.Solid phase assays, in general, are easier to perform than heterogeneousassay methods which require a separation step, such as precipitation,centrifugation, filtration, chromatography, or magnetism, becauseseparation of reagents is faster and simpler. Solid-phase assay devicesinclude microtiter plates, flow-through assay devices (e.g., lateralflow immunoassay devices), dipsticks, and immunocapillary orimmunochromatographic immunoassay devices.

In embodiments of the invention, the solid or semi-solid surface orcarrier is the floor or wall in a microtiter well, a filter surface ormembrane (e.g., a nitrocellulose membrane or a PVDF (polyvinylidenefluoride) membrane, such as an Immobilon™ membrane), polyethylenemembrane such as Porex® membrane, a hollow fiber, a beadedchromatographic medium (e.g., an agarose or polyacrylamide gel), amagnetic bead, a fibrous cellulose matrix, an HPLC matrix, an FPLCmatrix, a substance having molecules of such a size that the moleculeswith the peptide bound thereto, when dissolved or dispersed in a liquidphase, can be retained by means of a filter, a substance capable offorming micelles or participating in the formation of micelles allowinga liquid phase to be changed or exchanged without entraining themicelles, a water-soluble polymer, or any other suitable carrier,support or surface.

In some embodiments of the invention, the peptide is provided with (e.g.conjugated to) a suitable label which enables detection. Conventionallabels may be used which are capable, alone or in concert with othercompositions or compounds, of providing a detectable signal. Suitablelabels include, but are not limited to, enzymes (e.g., HRP,beta-galactosidase, alkaline phosphatase, etc.), fluorescent labels,quantum dots, radioactive labels, colored latex particles, andmetal-conjugated labels (e.g., metallic nanolayers, metallicnanomaterial-conjugated labels). Suitable metallic nanomaterialsinclude, but are not limited to, metallic nanoparticles, metallicnanoplates, and metallic nanoshells. Suitable metallic nanomateriallabels include, but are not limited to, gold particles or nanoplates,silver particles or nanoplates, copper particles or nanoplates, platinumparticles or nanoplates, palladium particles or nanoplates, cadmiumparticles or nanoplates, composite particles or nanoplates, gold hollowspheres, gold-coated silica nanoshells, and silica-coated gold shells.Metallic nanolayers suitable for detectable layers include nanolayerscomprised of cadmium, zinc, mercury, and noble metals, such as gold,silver, copper, and platinum. In some embodiments, the metallicnanolayers comprise composite gold-silver or silver nanolayers coatedwith gold.

Suitable detection methods include, e.g., detection of an agent which istagged, directly or indirectly, with a colorimetric assay (e.g., fordetection of HRP or beta-galactosidase activity), visual inspectionusing light microscopy, immunofluorescence microscopy, includingconfocal microscopy, or by flow cytometry (FACS), autoradiography (e.g.,for detection of a radioactively labeled agent), electron microscopy,immunostaining, subcellular fractionation, or the like. In oneembodiment, a radioactive element (e.g., a radioactive amino acid) isincorporated directly into a peptide chain; in another embodiment, afluorescent label is associated with a peptide via biotin/avidininteraction, association with a fluorescein conjugated antibody, or thelike. In one embodiment, a detectable specific binding partner for theantibody is added to the mixture. For example, the binding partner canbe a detectable secondary antibody or other binding agent (e.g., proteinA, protein G, protein L or combinations thereof) which binds to thefirst antibody. This secondary antibody or other binding agent can belabeled, e.g., with a radioactive, enzymatic, fluorescent, quantum dot,luminescent, metallic nanomaterial such as metallic nanoparticle,metallic nanoplate, or metallic nanoshell (e.g. colloidal gold), orother detectable label, such as an avidin/biotin system. In anotherembodiment, the binding partner is a peptide or population of peptidesof the invention, which can be conjugated directly or indirectly (e.g.via biotin/avidin interaction) to an enzyme, such as horseradishperoxidase or alkaline phosphatase or other signaling moiety. In suchembodiments, the detectable signal is produced by adding a substrate ofthe enzyme that produces a detectable signal, such as a chromogenic,fluorogenic, or chemiluminescent substrate.

A “detection system” for detecting bound peptide, as used herein, maycomprise a detectable binding partner, such as an antibody specific forthe peptide. In one embodiment, the binding partner is labeled directly.In another embodiment, the binding partner is attached to a signalgenerating reagent, such as an enzyme that, in the presence of asuitable substrate, can produce a detectable signal. A surface forimmobilizing the peptide may optionally accompany the detection system.

In some embodiments of the invention, the detection procedure comprisesvisibly inspecting the antibody-peptide complex for a color change, orinspecting the antibody-peptide complex for a physical-chemical change.Physical-chemical changes may occur with oxidation reactions or otherchemical reactions. They may be detected by eye, using aspectrophotometer, or the like.

A particularly useful assay format is a lateral flow immunoassay format.Antibodies to human or animal (e.g., dog, mouse, deer, etc.)immunoglobulins, or staph A, G, or L proteins, can be labeled with asignal generator or reporter (e.g., colloidal gold) that is dried andplaced on a glass fiber pad (sample application pad or conjugate pad).The diagnostic peptide or population of peptides of the invention isimmobilized on membrane, such as nitrocellulose or a PVDF(polyvinylidene fluoride) membrane (e.g., an Immobilon™ membrane). Whena solution of sample (blood, serum, etc.) is applied to the sampleapplication pad (or flows through the conjugate pad), it dissolves thelabeled reporter, which then binds to all antibodies in the sample. Theresulting complexes are then transported into the next membrane (PVDF ornitrocellulose containing the diagnostic peptide) by capillary action.If antibodies against the diagnostic peptide or population of peptidesare present in the sample, they bind to the diagnostic peptide orpopulation of peptides striped on the membrane, thereby generating asignal (e.g., a band that can be seen or visualized). An additionalantibody specific to the labeled antibody or a second labeled antibodycan be used to produce a control signal.

An alternative format for the lateral flow immunoassay comprises thepeptides or compositions of the invention being conjugated to a ligand(e.g., biotin) and complexed with labeled ligand receptor (e.g.,streptavidin-colloidal gold). The labeled peptide complexes can beplaced on the sample application pad or conjugate pad. Anti-humanIgG/IgM or anti-animal (e.g., dog, mouse, deer) IgG/IgM antibodies orother peptides of the invention are immobilized on a membrane, such asnitrocellulose or PVDF, or Porex® membrane at a test site (e.g., a testline). When sample is added to the sample application pad, antibodies inthe sample react with the labeled peptide complexes such that antibodiesthat bind to peptides of the invention become indirectly labeled. Theantibodies in the sample are then transported into the next membrane(PVDF, Porex® membrane, or nitrocellulose containing the diagnosticpeptide) by capillary action and bind to the immobilized anti-humanIgG/IgM or anti-animal IgG/IgM antibodies (or protein A, protein G,protein A/G fusion proteins, protein L, or combinations thereof) orimmobilized peptides of the invention. If any of the sample antibodiesare bound to the labeled peptides of the invention, the label associatedwith the peptides can be seen or visualized at the test site. Anotherembodiment of this type of lateral flow device in which the peptides ofthe invention are used both as the immobilized capture agent at a testsite and as a soluble labeled complex to react with antibodies in asample is shown in FIG. 1. In such embodiments, to amplify the detectionsignal, protein A, protein G, and/or protein A/G fusion proteinsconjugated to a detectable label (e.g., metallic nanomaterial such asnanoparticle, nanoplate, or nanoshell, HRP, β-GAL, ALP, fluorophore,colored latex particle or quantum dots) may be applied to the test sitewhere they will bind to the Fc region of any antibodies to Anaplasmaantigens captured by the immobilized peptides of the invention. Suitablecontrols for this assay can include, e.g., a chicken IgY-colloidal goldconjugate located at the sample application pad or conjugate pad, and ananti-chicken IgY antibody immobilized at a control site located proximalto the test site. Chicken anti-Protein A may also be used as theprocedural control line.

Another assay for the screening of blood products or other physiologicalor biological fluids is an enzyme linked immunosorbent assay, i.e., anELISA. Typically in an ELISA, isolated peptides or mixtures orpopulations of peptides of the invention are adsorbed to the surface ofa microtiter well directly or through a capture matrix (e.g., anantibody). Residual, non-specific protein-binding sites on the surfaceare then blocked with an appropriate agent, such as bovine serum albumin(BSA), heat-inactivated normal goat serum (NGS), or BLOTTO blockingbuffer (a buffered solution of nonfat dry milk which also contains apreservative, salts, and an antifoaming agent, available from ThermoScientific as Blocker™ BLOTTO). The well is then incubated with abiological sample suspected of containing specific anti-Anaplasma (e.g.,anti-A. phagocytophilum or anti-A. platys) antibody. The sample can beapplied neat, or more often it can be diluted, usually in a bufferedsolution which contains a small amount (0.1-5.0% by weight) of protein,such as BSA, NGS, or BLOTTO. After incubating for a sufficient length oftime to allow specific binding to occur, the well is washed to removeunbound protein and then incubated with an optimal concentration of anappropriate anti-immunoglobulin antibody (e.g., for human subjects, ananti-human immunoglobulin (aHuIg) from another animal, such as dog,mouse, cow, etc.) or another peptide or population of peptides of theinvention that is conjugated to an enzyme or other label by standardprocedures and is dissolved in blocking buffer. The label can be chosenfrom a variety of enzymes, including horseradish peroxidase (HRP),beta-galactosidase, alkaline phosphatase (ALP), glucose oxidase, β-GAL,etc. Sufficient time is allowed for specific binding to occur again,then the well is washed again to remove unbound conjugate, and asuitable substrate for the enzyme is added. Color is allowed to developand the optical density of the contents of the well is determinedvisually or instrumentally (measured at an appropriate wave length). Thecutoff OD value may be defined as the mean OD+3 standard deviations(SDs) of at least 50 serum samples collected from individuals from anarea where anaplasmosis is not endemic, or by other such conventionaldefinitions. In the case of a very specific assay, OD+2 SD can be usedas a cutoff value.

In one embodiment of an ELISA, a peptide or population of peptides ofthe invention is immobilized on a surface, such as a ninety-six-wellELISA plate or equivalent solid phase that is coated with streptavidinor an equivalent biotin-binding compound, such as avidin or neutravidin,at an optimal concentration in an alkaline coating buffer and incubatedat 4° C. overnight. After a suitable number of washes with standardwashing buffers, an optimal concentration of a biotinylated form of apeptide or composition of the invention, dissolved in a conventionalblocking buffer, is applied to each well. A sample is then added, andthe assay proceeds as above. Conditions for performing ELISA assays arewell-known in the art.

In another embodiment of an ELISA, a peptide or population of peptidesof the invention is immobilized on a surface, such as a ninety-six-wellELISA plate or equivalent solid phase via a fusion partner, e.g., BSA orMAPS. A sample is then added and the assay proceeds as above.

An alternative format for the ELISA assay features the peptide(s) of theinvention being attached (e.g., fused) to an appropriate enzyme, such asHRP. Steps for carrying out such an ELISA include: coating the wells ofa plate with anti-dog, anti-cat, or anti-human IgG/IgM; incubatingsamples suspected of containing antibodies to the peptides of theinvention with the immobilized anti-species IgG/IgM; removing unreactedsample and washing the wells with a suitable wash buffer; applyingenzyme-coupled (e.g., HRP-coupled) peptide or population of peptides ofthe invention and allowing it to react with any captured anti-Anaplasmaantibodies; and visualizing the enzyme-coupled peptide by applying anappropriate enzyme substrate (e.g., TMB).

In another embodiment, the methods comprise an agglutination assay. Forexample, in certain embodiments, metallic nanoparticles, metallicnanoplates, or metallic nanoshells (e.g., colloidal gold, etc.) or latexbeads are conjugated to peptides or compositions of the invention.Subsequently, the biological fluid is incubated with the bead/peptideconjugate, thereby forming a reaction mixture. The reaction mixture isthen analyzed to determine the presence of the antibodies. In certainembodiments, the agglutination assays comprise the use of a secondpopulation of particles, such as metallic nanoparticles, metallicnanoplates, or metallic nanoshells (e.g., colloidal gold, etc.) or latexbeads, conjugated to (1) antibodies specific to the peptides orcompositions of the invention, in the case of a competition assay, or(2) antibodies capable of detecting sample antibodies (e.g., anti-humanIgG or IgM antibodies, anti-dog IgG or IgM antibodies, anti-cat IgG orIgM antibodies, etc.), in the case of a sandwich assay. Suitableagglutination methods can comprise centrifugation as a means ofassessing the extent of agglutination.

In still other embodiments, peptide or compositions of the invention areelectro- or dot-blotted onto nitrocellulose paper. Subsequently, asample, such as a biological fluid (e.g., serum or plasma) is incubatedwith the blotted antigen, and antibody in the biological fluid isallowed to bind to the antigen(s). The bound antibody can then bedetected, e.g., by standard immunoenzymatic methods or by visualizationusing metallic nanomaterial such as nanoparticles, nanoplates, ornanoshells coupled to secondary antibodies or other antibody bindingagents, such as protein A, protein G, protein A/G fusion proteins,protein L, or combinations thereof.

It should be understood by one of skill in the art that any number ofconventional protein assay formats, particularly immunoassay formats,may be designed to utilize the isolated peptides or populations ofpeptides of this invention for the detection of Anaplasma antibodies andinfection by pathogenic Anaplasma (e.g., A. phagocytophilum, A. platys,or A. marginale) in a subject. This invention is thus not limited by theselection of the particular assay format, and is believed to encompassassay formats that are known to those of skill in the art.

In certain embodiments, the sample used in the methods is a bodilyfluid, such as blood, plasma, serum, cerebrospinal fluid, urine, orsaliva. In other embodiments, the sample is a tissue (e.g., a tissuehomogenate) or a cell lysate. In certain embodiments, the sample is froma wild animal (e.g., a deer or rodent, such as a mouse, chipmunk,squirrel, etc.). In other embodiments, the sample is from a lab animal(e.g., a mouse, rat, guinea pig, rabbit, monkey, primate, etc.). Inother embodiments, the sample is from a domesticated or feral animal(e.g., a dog, a cat, a horse). In still other embodiments, the sample isfrom a human.

Much of the preceding discussion is directed to the detection ofantibodies against pathogenic Anaplasma. However, it is to be understoodthat the discussion also applies to the detection of primed T-cells,either in vitro or in vivo.

It is expected that a cell-mediated immune response (e.g., a T-helperresponse) is generated, since IgG is produced. It is therefore expectedthat it will be possible to determine the immunological reactivitybetween primed T-cells and a peptide of the invention. In vitro this canbe done by incubating T-cells isolated from the subject with a peptideor population of peptides of the invention and measuring theimmunoreactivity, e.g., by measuring subsequent T-cell proliferation orby measuring release of cytokines from the T-cells, such as IFN-γ. Thesemethods are well-known in the art.

When a method of the invention is carried out in vivo, any of a varietyof conventional assays can be used. For example, one can perform anassay in the form of a skin test, e.g., by intradermally injecting, inthe subject, a peptide or population of peptides of the invention. Apositive skin reaction at the location of injection indicates that thesubject has been exposed to and infected with a pathogenic Anaplasmaspecies capable of causing anaplasmosis, and a negative skin response atthe location of injection indicates that the subject has not been soexposed/infected. This or other in vivo tests rely on the detection of aT-cell response in the subject.

The present invention also provides a method for diagnosing anaplasmosisin a subject. Anaplasmosis in humans was previously known as humangranulocytic ehrlichiosis and has more recently been termed humangranulocytic anaplasmosis. Some strains of Anaplamsa (e.g., A. platys)cause cyclic thrombocytopenia in animals (e.g. in dogs, the disease istermed Infectious Canine Cyclic Thrombocytopenia (ICCT)). Thus, thepresent invention also provides a method for diagnosing cyclicthrombocytopenia or ICCT in a subject. The subject can be a subjectsuspected of having antibody against a causative agent of anaplasmosisor cyclic thrombocytopenia. The diagnostic method is useful fordiagnosing subjects exhibiting the clinical symptoms of anaplasmosis orcyclic thrombocytopenia. Clinical symptoms of human anaplasmosis (i.e.,human granulocytic anaplasmosis) include, but are not limited to, fever,headache, malaise, chills, myalgia, abdominal pain, cough, confusion,thrombocytopenia, leukopenia, and elevated serum transaminase levels.Clinical symptoms of anaplasmosis or cyclic thrombocytopenia in animals(e.g. canines) include, but are not limited to, profound anemia,tachycardia, dyspnea, diarrhea, anorexia, weight loss, ataxia,leukopenia, lethargy, lymphadenomegaly, pale mucous membranes, fever,mucopurulent nasal discharge, inappetance, weak or painful limbs, andlameness.

In some embodiments, the methods comprise contacting a sample from thesubject with a peptide of the invention, and detecting formation of anantibody-peptide complex comprising said peptide, wherein formation ofsaid complex is indicative of the subject having anaplasmosis or cyclicthrombocytopenia. In certain embodiments, the methods comprisecontacting the sample with a population of two, three, four, or more(e.g., 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100,150, 200, 250, 300, 400, 500, or more) different peptides of theinvention and detecting formation of an antibody-peptide complexcomprising said one or more peptides in the population, whereinformation of the complex is indicative of the subject havinganaplasmosis or cyclic thrombocytopenia. For instance, in one particularembodiment, the methods comprise contacting the sample with a populationof two or more different isolated peptides, wherein each isolatedpeptide comprises a sequence of SEQ ID NO: 1. In another particularembodiment, the methods comprise contacting the sample with a populationof two or more different isolated peptides, wherein each isolatedpeptide comprises a sequence of SEQ ID NO: 3. In still anotherembodiment, the methods comprise contacting the sample with a populationof two or more different isolated peptides, wherein each isolatedpeptide comprises a sequence of SEQ ID NO: 4. In some embodiments, themethods comprise contacting the sample with a population of two or moredifferent isolated peptides, wherein each isolated peptide comprises asequence of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 543.

In certain embodiments, the methods comprise contacting the sample witha mixture of one or more peptides of the invention and one or more otherpeptides (e.g., an Ehrlichia peptide, or antigenic fragment or epitopethereof, or a Borrelia peptide, or antigenic fragment or epitopethereof) Co-infections with Anaplasma and Ehrlichia or Borrelia speciesare common. Thus, diagnostic methods of the invention that employpopulations of peptides comprising the Anaplasma peptides describedherein and one or more peptides from an Ehrlichia or Borrelia speciesare useful for detecting such co-infections. Exemplary Ehrlichiaantigenic peptides that may be used with the Anaplasma peptides of theinvention are described in U.S. application Ser. No. 14/052,296 and U.S.Pat. No. 8,828,675, both of which are incorporated by reference hereinin their entireties. Exemplary Borrelia antigenic peptides that may beused with the Anaplasma peptides of the invention are described in U.S.Pat. Nos. 8,568,989 and 8,758,772, both of which are incorporated byreference herein in their entireties. Other Ehrlichia and Borreliaantigens are known in the art and may be used in combination with theAnaplasma peptides of the invention to detect co-infections in asubject.

In certain embodiments, the peptide or each peptide in the population isan isolated (e.g., synthetic and/or purified) peptide. In someembodiments, the peptide or population of different peptides is attachedto or immobilized upon a substrate (e.g., a solid or semi-solidsupport). For example, in certain embodiments, the substrate is a beador plurality of beads (e.g., a colloidal or other type of particle ormetallic nanomaterial such as nanoparticle, nanoplate, or nanoshell), aflow path in a lateral flow immunoassay device (e.g., a porousmembrane), a flow path in an analytical or centrifugal rotor, a blot(e.g., a Western blot, dot blot, or slot blot), a tube or a well (e.g.,in a plate suitable for an ELISA assay), or a sensor (e.g., anelectrochemical, optical, or opto-electronic sensor). In someembodiments, the peptide or population of peptides is attached to orimmobilized upon a solid support through a metallic nanolayer that, insome embodiments, may be comprised of cadmium, zinc, mercury, or a noblemetal (e.g., gold, silver, copper, and platinum).

There are a number of different conventional assays for detectingformation of an antibody-peptide complex comprising a peptide of theinvention. For example, the detecting step can comprise performing anELISA assay, performing a lateral flow immunoassay, performing anagglutination assay, performing a wavelength shift assay, analyzing thesample using a Western blot, a slot blot, or a dot blot, performing anIndirect Fluorescent Antibody test, analyzing the sample in ananalytical or centrifugal rotor, or analyzing the sample with anelectrochemical, optical, or opto-electronic sensor. These differentassays are described above and/or are well-known to those skilled in theart.

In certain embodiments, the sample used in the diagnostic methods of theinvention is a bodily fluid, such as blood, plasma, serum, cerebrospinalfluid, urine, or saliva. In other embodiments, the sample is a tissue(e.g., a tissue homogenate) or a cell lysate. In certain embodiments,the subject is a wild animal (e.g., a deer or rodent, such as a mouse,chipmunk, squirrel, etc.). In other embodiments, the subject is a labanimal (e.g., a mouse, rat, guinea pig, rabbit, monkey, primate, etc.).In other embodiments, the subject is a domesticated or feral animal(e.g., a dog, a cat, a horse). In still other embodiments, the subjectis a human.

The present invention also includes a method for identifying the speciesof Anaplasma infecting a subject. Such methods aid in the treatment ofthe infection in the subject because treatment regimens may differdepending on the particular Anaplasma species causing the infection. Thespecies identification methods are also useful in the epidemiology ofAnaplasma infections and anaplasmosis. In certain embodiments, themethod distinguishes between infections caused by A. phagocytophilum andinfections caused by A. platys. In one embodiment, the method comprisescontacting a sample from the subject with a first peptide or populationof isolated peptides and a second peptide or population of isolatedpeptides, wherein the first peptide or population of isolated peptidesspecifically binds to antibodies against antigens from multipleAnaplasma species, and wherein the second peptide or population ofisolated peptides specifically binds to antibodies against antigens froma single Anaplasma species. Formation of a first antibody-peptidecomplex comprising said first peptide or one or more peptides in thefirst population and formation of a second antibody-peptide complexcomprising said second peptide or one or more peptides in the secondpopulation are detected, wherein formation of both the first and secondantibody-peptide complexes indicates that the subject is infected withthe Anaplasma species that is specifically bound by the second peptideor population of isolated peptides.

In some embodiments, the first peptide or first population of peptidesspecifically binds to antibodies against antigens from A.phagocytophilum, A. platys, and A. marginale. In certain embodiments,the first peptide or first population of peptides specifically binds toantibodies against antigens from both A. phagocytophilum and A. platys.For example, in one embodiment, the first peptide comprises a sequenceof SEQ ID NO: 3. In another embodiment, the first population of peptidescomprises three or more different peptides, wherein each peptide in thepopulation comprises a sequence of SEQ ID NO: 3 or a fragment thereof Insuch embodiments, the first population of peptides may comprise three ormore peptides listed in Table 3 (i.e., three or more peptides comprisingor consisting of sequences of SEQ ID NOs: 199-350).

In certain embodiments, the second peptide or second population ofpeptides specifically binds to antibodies against antigens from A.platys. For instance, in one embodiment, the second peptide comprises asequence of SEQ ID NO: 4. In another embodiment, the second populationof peptides comprises three or more different peptides, wherein eachpeptide in the population comprises a sequence of SEQ ID NO: 4 or afragment thereof. In such embodiments, the first population of peptidesmay comprise three or more peptides listed in Table 4 (i.e., three ormore peptides comprising or consisting of sequences of SEQ ID NOs:351-398). In other embodiments, the second peptide or second populationof peptides may comprise a sequence of SEQ ID NOs. 6-8. In relatedembodiments, the second population of peptides comprises three or moredifferent peptides listed in Tables 6 or 7 (i.e., three or more peptidescomprising or consisting of sequences of SEQ ID NOs: 407-464).

In such embodiments in which the second peptide or second population ofpeptides specifically binds to antibodies against antigens from A.platys, formation of both the first and second antibody-peptidecomplexes indicates that the subject is infected with A. platys. Inrelated embodiments, formation of the first antibody-peptide complex,but not the second antibody-peptide complex indicates that the subjectis infected with A. phagocytophilum . For instance, in certainembodiments, the first population of isolated peptides is defined by SEQID NO: 3 and the second population of isolated peptides is defined bySEQ ID NO: 4, and formation of both the first and secondantibody-peptide complexes is detected indicating that the subject isinfected with A. platys. In other embodiments, the first population ofisolated peptides is defined by SEQ ID NO: 3 and the second populationof isolated peptides is defined by any one of SEQ ID NOs: 6 to 8, andformation of both the first and second antibody-peptide complexes isdetected indicating that the subject is infected with A. platys. In someembodiments, the first population of isolated peptides is defined by SEQID NO: 3 and the second population of isolated peptides is defined bySEQ ID NO: 4, and formation of the first antibody-peptide complex, butnot the second antibody-peptide complex is detected indicating that thesubject is infected with A. phagocytophilum. In other embodiments, thefirst population of isolated peptides is defined by SEQ ID NO: 3 and thesecond population of isolated peptides is defined by any one of SEQ IDNOs: 6 to 8, and formation of the first antibody-peptide complex, butnot the second antibody-peptide complex is detected indicating that thesubject is infected with A. phagocytophilum.

In alternative embodiments, the second peptide or second population ofpeptides specifically binds to antibodies against antigens from A.phagocytophilum . For instance, in one embodiment, the second peptidecomprises a sequence of SEQ ID NO: 1. In another embodiment, the secondpopulation of peptides comprises three or more different peptides,wherein each peptide in the population comprises a sequence of SEQ IDNO: 1 or a fragment thereof. In such embodiments, the first populationof peptides may comprise three or more peptides listed in Table 1 (i.e.,three or more peptides comprising or consisting of sequences of SEQ IDNOs: 10-117). In other embodiments, the second peptide or secondpopulation of peptides may comprise a sequence of SEQ ID NOs. 2, 5, or9. In related embodiments, the second population of peptides comprisesthree or more different peptides listed in Tables 2, 5, or 8 (i.e.,three or more peptides comprising or consisting of sequences of SEQ IDNOs: 118-198, 399-406, or 465-542).

In such embodiments in which the second peptide or second population ofpeptides specifically binds to antibodies against antigens from A.phagocytophilum , formation of both the first and secondantibody-peptide complexes indicates that the subject is infected withA. phagocytophilum. In related embodiments, formation of the firstantibody-peptide complex, but not the second antibody-peptide complexindicates that the subject is infected with A. platys. For instance, incertain embodiments, the first population of isolated peptides isdefined by SEQ ID NO: 3 and the second population of isolated peptidesis defined by SEQ ID NO: 1, and formation of both the first and secondantibody-peptide complexes is detected indicating that the subject isinfected with A. phagocytophilum . In other embodiments, the firstpopulation of isolated peptides is defined by SEQ ID NO: 3 and thesecond population of isolated peptides is defined by any one of SEQ IDNOs: 2, 5, or 9, and formation of both the first and secondantibody-peptide complexes is detected indicating that the subject isinfected with A. phagocytophilum . In some embodiments, the firstpopulation of isolated peptides is defined by SEQ ID NO: 3 and thesecond population of isolated peptides is defined by SEQ ID NO: 1, andformation of the first antibody-peptide complex, but not the secondantibody-peptide complex is detected indicating that the subject isinfected with A. platys. In other embodiments, the first population ofisolated peptides is defined by SEQ ID NO: 3 and the second populationof isolated peptides is defined by any one of SEQ ID NOs: 2, 5, or 9,and formation of the first antibody-peptide complex, but not the secondantibody-peptide complex is detected indicating that the subject isinfected with A. platys.

The first and second antibody-peptide complexes can be detected usingvarious methods including, but not limited to, performing an ELISAassay, running a lateral flow assay, performing an agglutination assay,performing a Western blot, a slot blot, or dot blot, performing awavelength shift assay, performing an Indirect Fluorescent Antibodytest, or running the sample through an analytical or centrifugal rotor.Such methods and devices for use in the methods are described in detailabove.

In other embodiments, the method for identifying the species ofAnaplasma infecting a subject comprises contacting a sample from thesubject with a first population of peptides and a cell extract of asingle Anaplasma species, wherein the first population of isolatedpeptides specifically binds to antibodies against antigens from multipleAnaplasma species; detecting formation of a first antibody-peptidecomplex comprising one or more peptides in the first population; anddetecting formation of an antibody-cell extract complex comprising oneor more components in the cell extract, wherein formation of both thefirst antibody-peptide complex and the antibody-cell extract complexindicates that the subject is infected with the Anaplasma species thatproduced the cell extract. In some embodiments, the cell extract is fromA. phagocytophilum.

A cell extract comprises components of cells. It can be generated bylysing cells (e.g., with detergents) and removing unwanted components(e.g., using centrifugation to remove insoluble matter such as membranefragments, vesicles, and nuclei). A cell extract can be a whole-celllysate or partial-cell lysate. Cell extracts usually consist mostly ofcytosol. Various methods of making cell extracts are well known to thoseof skill in the art. Commercial kits are available for generating cellextracts.

Kits

In yet another aspect, the invention provides kits for use in thedetection and diagnostic assays described herein. In some embodiments,the kits comprise one or more peptides of the invention. In certainembodiments, the kits comprise a population of peptides of theinvention. The peptides can comprise a sequence of SEQ ID NO: 1, SEQ IDNO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ IDNO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 543, or fragments thereof.In one embodiment, the kits comprise two or more populations of peptidesof the invention. For example, in one embodiment, the kits comprise afirst population of peptides defined by SEQ ID NO: 3 and a secondpopulation of peptides defined by SEQ ID NO: 4. In particularembodiments, the peptides are attached to or immobilized on a solidsupport. In some embodiments, the peptides are attached to orimmobilized on a solid support through a metallic nanolayer (e.g.,cadmium, zinc, mercury, gold, silver, copper, or platinum nanolayer). Incertain embodiments, the solid support is a bead or plurality of beads(e.g., a colloidal particle or a metallic nanomaterial such asnanoparticles, nanoplates, or nanoshells), a flow path in a lateral flowimmunoassay device, a flow path in an analytical or centrifugal rotor, atube or a well (e.g., in a plate), or a sensor (e.g., anelectrochemical, optical, or opto-electronic sensor).

Reagents for particular types of assays can also be provided in kits ofthe invention. Thus, the kits can include a population of beads (e.g.,suitable for an agglutination assay or a lateral flow assay), or a plate(e.g., a plate suitable for an ELISA assay). In other embodiments, thekits comprise a device, such as a lateral flow immunoassay device, ananalytical or centrifugal rotor, a Western blot, a dot blot, a slotblot, or an electrochemical, optical, or opto-electronic sensor. Thepopulation of beads, the plate, and the devices are useful forperforming an immunoassay. For example, they can be useful for detectingformation of an antibody-peptide complex comprising an antibody from asample and a peptide of the invention. In certain embodiments, apeptide, a population of different peptides of the invention, or apeptide composition of the invention is attached to or immobilized onthe beads, the plate, or the device.

In addition, the kits can include various diluents and buffers, labeledconjugates or other agents for the detection of specifically boundantigens or antibodies (e.g. labeling reagents), and othersignal-generating reagents, such as enzyme substrates, cofactors andchromogens. In one embodiment, the kits comprise a labeling reagentcapable of binding to an antibody that recognizes an epitope of one ormore peptides of the invention. For instance, in some embodiments, thekit comprises an anti-human, anti-canine, or anti-feline IgG or IgMantibody conjugated to a detectable label (e.g., a metallic nanomaterialsuch as a nanoparticle, a nanoplate, or a metallic nanoshell, a metallicnanolayer, a fluorophore, a quantum dot, a colored latex particle, or anenzyme) as a labeling reagent. In other embodiments, the kit comprisesprotein A, protein G, protein A/G fusion proteins, protein L, orcombinations thereof conjugated to a detectable label (e.g., a metallicnanomaterial such as a metallic nanoparticle, a metallic nanoplate, ametallic nanoshell, a metallic nanolayer, a fluorophore, a quantum dot,a colored latex particle, or an enzyme) as a labeling reagent. Anexemplary protein A/G fusion protein combines four Fc-binding domainsfrom protein A with two from protein G. See, e.g., Sikkema, J. W. D.,Amer. Biotech. Lab, 7:42, 1989 and Eliasson et al., J. Biol. Chem. 263,4323-4327, 1988, both which are hereby incorporated by reference intheir entireties. In still other embodiments, the labeling reagents ofthe kit are a second population of peptides of the invention conjugatedto a detectable label (e.g., a metallic nanomaterial such as a metallicnanoparticle, a metallic nanoplate, a metallic nanoshell, a metallicnanolayer, a fluorophore, a colored latex particle, or an enzyme). Thesecond population of peptides can be the same as or different than thefirst population of peptides, which may optionally be attached to orimmobilized upon a solid support.

Other components of a kit can easily be determined by one of skill inthe art. Such components may include coating reagents, polyclonal ormonoclonal capture antibodies specific for a peptide of the invention,or a cocktail of two or more of the antibodies, purified orsemi-purified extracts of these antigens as standards, monoclonalantibody detector antibodies, an anti-mouse, anti-dog, anti-cat,anti-chicken, or anti-human antibody conjugated to a detectable label,indicator charts for colorimetric comparisons, disposable gloves,decontamination instructions, applicator sticks or containers, a samplepreparatory cup, etc. In one embodiment, a kit comprises buffers orother reagents appropriate for constituting a reaction medium allowingthe formation of a peptide-antibody complex.

Such kits provide a convenient, efficient way for a clinical laboratoryto diagnose infection by a pathogenic Anaplasma species, such as A.phagocytophilum, A. platys, or A. marginale. Thus, in certainembodiments, the kits further comprise an instruction. For example, incertain embodiments, the kits comprise an instruction indicating how touse a peptide or population of peptides of the invention to detect anantibody to one or more Anaplasma antigens or to diagnose anaplasmosisor cyclic thrombocytopenia. In certain embodiments, the kits comprise aninstruction indicating how to use a population of beads, a plate, or adevice (e.g., comprising a peptide or a population of different peptidesof the invention) to detect an antibody to one or more Anaplasmaantigens or to diagnose anaplasmosis or cyclic thrombocytopenia.

The peptides, compositions and devices comprising the peptides, kits andmethods of the invention offer a number of advantages. For example, theyallow for simple, inexpensive, rapid, sensitive and accurate detectionof anaplasmosis or cyclic thrombocytopenia, and avoid serologiccross-reactivity with other conditions with similar symptoms. Thisallows for an accurate diagnosis. Furthermore, a diagnostic test of theinvention (e.g., an ELISA assay, lateral flow immunoassay, oragglutination assay) is useful in serum samples that contain anti-MSP2/p44 or anti-OMP/p44 antibodies or other antibodies produced inresponse to a vaccine based on the outer surface proteins of Anaplasma.

The following examples illustrate various aspects of the invention. Theexamples should, of course, be understood to be merely illustrative ofonly certain embodiments of the invention and not to constitutelimitations upon the scope of the invention.

EXAMPLES Example 1 ELISA Assay

Two different populations of peptides were synthesized using standardsynthesis procedures. Each peptide in the first population of peptides(APL-ID1) contained a sequence of SEQ ID NO: 3. The first population ofpeptides specifically binds to antibodies elicited by both A.phagocytophilum and A. platys. Each peptide in the second population ofpeptides (APL-ID2) contained a sequence of SEQ ID NO: 4. The secondpopulation of peptides specifically binds to antibodies elicitedprimarily by A. platys.

Each peptide in the two populations was linked separately to the carrierprotein bovine serum albumin (BSA) using thio-ether chemistry. Theresulting BSA-peptide conjugates were used as capture entities in96-well ELISA plates to create two separate ELISA assays (one populationof peptides per plate). The plates were blocked with 5% non-fat milkpowder dissolved in 25 mM borate buffer (pH9.5) to prevent undesirablenon-specific binding.

Dogs were inoculated with A. phagocytophilum-infected tick cell culturesto initiate exposure of the dogs to A. phagocytophilum . Stabilizedblood obtained from animals known to harbor A. platys infection asdetermined by PCR and microscopic examination was inoculated into aseparate group of dogs for initiating infection with A. platys. Bloodsamples from each group of inoculated dogs were collected at variousdays following inoculation.

Plasma prepared from the blood samples was tested for reactivity withthe APL-ID1 and APL-ID2 peptides using the ELISA plates described above.The plasma samples were diluted 1:250 to 1:1000 in blocking solution andadded to blocked wells in each of the two ELISA plates. After a one-hourincubation period, the unreacted materials were removed by washing themicro wells. The specifically captured anti-peptide dog IgG or IgM weredetected by reaction with HRP-labeled Protein A. HRP was assayed using acommercial TMB substrate. The optical density of each well was read at650 nm with a plate reader.

Reactivity of plasma samples obtained from an A. platys-infected dog(15-13) dog and an A. phagocytophilum-infected dog (3-13) with APL-ID1peptides and APL-ID2 peptides are shown in FIGS. 5 and 6, respectively.The samples from the A. phagocytophilum-infected dog (dog 3-13) showedsignificant reactivity with APL-ID1 peptides, whereas the reactivity ofsuch samples with APL-ID2 peptides was much lower. In contrast, samplesfrom the A. platys-infected dog (dog 15-13) showed similar reactivitytowards both populations of peptides. These experimental results showthat populations of peptides defined by SEQ ID NO: 3 (APL-ID1) and SEQID NO: 4 (APL-ID2) have a high degree of sensitivity in detecting thepresence of antibodies to Anaplasma antigens. In addition, the resultsshow that these two populations of peptides can be used to identify theinfecting species of Anaplasma. A sample that tests positive forreactivity with APL-ID1 peptides, but not APL-ID2 peptides is positivefor A. phagocytophilum, whereas a sample that tests positive forreactivity for both peptides is positive for A. platys.

Example 2 Lateral Flow Assay

A lateral flow immunoassay in a double antigen sandwich format wasconstructed to detect the presence of antibodies specific for Anaplasmaantigens. A population of peptides comprising peptides with a sequenceof SEQ ID NO: 3 (APL-ID1), SEQ ID NO: 6 (APL-ID5.1), or SEQ ID NO: 7(APL-ID6) was linked to BSA and the resulting complexes were used bothas test conjugate (peptides labeled with gold nanoparticles) and ascapture (immobilized at the test line of the device). The signalproduced at the test line was enhanced by Protein A and Protein G-goldconjugates (amplifier) added to the labeled peptide conjugate. Thedevice is depicted in FIG. 7.

The operation of the device is illustrated in FIG. 8. To conduct theassay, one drop of anti-coagulated whole blood, serum, or plasma isapplied to the sample port of the device. The blood separation padfilters blood cells from whole blood. Plasma (or serum) mobilizes andbinds specifically to the test conjugate present on the conjugate padand any formed antibody-peptide complexes migrate to the nitrocellulosemembrane containing the test and the control regions. The application ofa chase buffer after sample application moves the free and the boundtest conjugates through the nitrocellulose membrane towards the upperabsorbent pad. The labeled peptide-antibody complexes move to the testline where immobilized peptides capture labeled peptide-antibodycomplexes via the second binding sites on the antibodies. Protein A-goldand Protein G-gold conjugates in the conjugate mixture bind to capturedantibodies amplifying the detection signal. The appearance of one redline at the test site and a second red line at the control siteindicates the presence of antibodies to Anaplasma spp. (e.g.,phagocytophilum or platys) in the sample. The appearance of a red lineat only the control site indicates the absence of antibodies to all ofthe Anaplasma spp. in the sample. The test is considered invalid if (i)a signal at the test line appears but no signal at the control line ispresent or (ii) no signal is observed at either the control or testlines.

Ninety-five dog plasma samples positive for Anaplasma spp. as determinedby indirect immunofluorescence assay, IDEXX SNAP 4DX Plus™, and ELISAusing the same peptide mixture, were tested in the lateral flow device.In addition, fifty-one dog plasma samples that were determined to benegative for Anaplasma spp. by the same methods were also evaluated.Each sample was tested twice in the device. Each test was performed by adifferent operator. At the end of the test period, each test was markedby the operator as either positive or negative. Additionally, scannedimages of each test were obtained and analyzed by the ImageJ method. Atest where both operators agreed on the designation was recorded as thesame designation (pos/neg). Where operators disagreed, a third test wasrun by a third operator and taken as the final result (pos/neg) for thatsample. The results are summarized in Table 9 below. The lateral flowassay had a sensitivity of 97.9% and a specificity of 90.2%. Thisexample demonstrates that a population of peptides comprising peptideshaving a sequence of SEQ ID NO: 3, SEQ ID NO: 6, or SEQ ID NO: 7 caneffectively detect antibodies against Anaplasma antigens when employedin a lateral flow assay format.

TABLE 9 Lateral Flow Assay Results of Known Anaplasma-Positive andNegative Samples Negative by Positive by Lateral Flow Lateral Flow No.of known negative samples 46 5 No. of known positive samples 2 93

Example 3 Indirect Fluorescent Antibody Assay

An indirect fluorescent antibody test is constructed using latex beadscoated with one or more peptides of the invention. In certainembodiments, the peptides defined by SEQ ID NO: 3 (APL-ID1), SEQ ID NO:4 (APL-ID2), and/or SEQ ID NO: 6 (APL-ID5.1) are used. The peptides ofthe invention are coated onto maleimide-derivatized latex beads usingthio-ether chemistry. Alternatively, the peptides of the invention maybe conjugated to BSA via thio-ether or similar chemistries and arepassively absorbed on to latex beads. A population of such beads is thenimmobilized on a glass slide using known techniques.

To conduct the assay, one drop of serum or plasma (diluted appropriatelywith a suitable buffer) from dogs suspected of having anti-Anaplasmaantibodies, is applied to the glass slide coated with latex beads.Following a suitable incubation time, the unreacted materials are washedaway and a drop of fluorescently labeled anti-dog IgG (or IgM) isapplied and the slides are incubated for an additional time period. Thefinal preparation is viewed under a fluorescent microscope to determinefluorescently tagged latex beads. The classification of the testserum/plasma as positive or negative is based on comparison withappropriate controls. An enzyme label may be used in place of thefluorescent label in which case the visualization step employs an enzymesubstrate. For example, anti-dog IgG/IgM labeled with alkalinephosphatase can be visualized by exposing the slide to a BCIP-nitro BTsubstrate. Labeled Protein A, Protein G, or Protein A/G fusion can beused in place of labeled anti-dog IgG and anti-dog IgM to detectantibodies bound to the peptide-coated beads.

Example 4 Identification of the Species of Anaplasma Infecting Dogs inUnknown Samples

This example demonstrates successful identification of the species ofAnaplasma infecting dogs using the peptide populations of the inventionand Anaplasma cell extracts.

Forty one dog plasma samples, which were all tested and classified byvisual inspection as positive for Anaplasma infection using the IDEXXSNAP 4DX Plus™ assay, were tested in an ELISA assay similar to thatdescribed in Example 1. Three 96-well ELISA plates were coated withvarious peptides or cell extract (prepared using a commercial kit fromSigma-Aldrich) at room temperature for 1 hour. Plate 1 was coated with100 μL/well of a mixture of three peptide populations: APL-ID1 (SEQ IDNO: 3, final concentration 7 μg/mL), APL-ID5.1 (SEQ ID NO: 6, finalconcentration 7 μg/mL), and APL-ID6 (SEQ ID NO: 7, final concentration 7μg/mL). Plate 2 was coated with 100 μL/well of a mixture of two peptidepopulations: APL-ID5.1 (SEQ ID NO: 6, final concentration 7 μg/mL), andAPL-ID6 (SEQ ID NO: 7, final concentration 7 μg/mL). Plate 3 was coatedwith 100 μL/well of an A. phagocytophilum whole-cell lysate (finalconcentration 5 μg/mL). The peptide mixture on plate 1 specificallybinds to antibodies elicited by both A. phagocytophilum and A. platys.The peptide mixture on plate 2 specifically binds to antibodies elicitedprimarily by A. platys. The whole-cell lysate on plate 3 specificallybinds to antibodies elicited primarily by A. phagocytophilum . Theplates were then washed.

The plates were then blocked with 300 μL/well of 7% non-fat milk in 250mM borate buffer (pH9.5) at room temperature for 1 hour to preventundesirable non-specific binding. The plates were washed again.

Plasma samples from dogs with or without Anaplasma infection (the“unknown samples”) were diluted 1/100 in 7% milk, and 100 μL/well ofeach sample were added to the ELISA plates and incubated at roomtemperature for 1 hour. The plates were washed again.

The plates were then incubated with 100 μL/well of Protein A-HRPconjugate (diluted 1:1000) at room temperature for 1 hour. The plateswere washed again, and 100 μL/well of substrate (TMB) was added andincubated at room temperature for 10 minutes. OD readings of all thesamples were obtained and compared to standard curves. For plate 1 andplate 2 (the two “peptide” plates), serial dilutions of pooled positivesamples were used to create standard curves. For plate 3 (the lysateplate), a two point curve was made using a negative sample and a caninesample from a dog which was experimentally infected with A.phagocytophilum (“3-13”).

Species identification results of these samples using the peptide-cellextract ELISA, along with the results of the SNAP test and an indirectimmunofluorescence assay (IFA), are shown in Table 10. Both the SNAP andthe IFA tests only detected Anaplasma at the genus level and could notbe used to determine the species of Anaplasma.

TABLE 10 Identification of Anaplasma Species in Unknown SamplesAnaplasma spcies SNAP 4DX determined with Plus ™ Sample Combo platysphago peptides and (Anaplasma) ID Score^(a) Score^(b) WCL score^(c) cellextract^(d) result^(e) IFA titer^(f) 1 214 986 315 platys 31.6% 25600 29 1 97 NEG 40.1% 25600 3 37 19 107 phago 14.7% 12800 4 17 5 151 phago30.1% 25600 5 68 24 38 phago 18.3% 6400 6 37 27 47 phago 23.8% 6400 7 216 30 phago 7.0% 3200 8 10 2 39 phago 18.7% 6400 9 29 2 172 phago 32.0%25600 10 12 1 86 phago 14.5% 12800 11 6 −1 89 NEG 12.4% 3200 12 165 0110 phago 39.0% 25600 13 52 2 362 phago 37.3% 25600 14 18 −1 69 phago40.0% 25600 15 49 3 206 phago 39.3% 25600 16 26 10 79 phago 22.2% 320017 34 4 30 phago 25.3% 6400 18 40 2 82 phago 34.3% 25600 19 6 2 51 NEG11.4% 3200 20 22 0 141 phago 26.8% 1600 21 302 245 8 platys 25.9% 1280022 91 33 10 platys 17.5% 1600 23 12 7 24 phago 46.3% 51200 24 483 714 6platys 11.7% 6400 25 61 53 18 platys 19.7% 6400 26 117 122 49 platys7.3% 51200 27 244 140 16 platys 27.7% 12800 28 25 37 15 platys 28.2%12800 29 56 72 21 platys 17.9% 12800 30 156 250 2 platys 9.2% 1600 31517 880 17 platys 39.3% 12800 32 23 25 30 phago 8.3% 3200 33 6 4 24 NEG20.9% 25600 34 18 23 5 platys 13.8% 1600 35 82 79 33 platys 45.0% 640036 35 27 18 platys 17.1% 3200 37 354 256 26 platys 49.0% 6400 38 6 19 36NEG 43.9% 25600 39 20 45 20 platys 19.7% 12800 40 60 186 8 platys 1.3%1600 41 2 1 46 NEG 4.9% <1:50 (NEG) ^(a)Combo Score was calculated bycomparing OD readings of unknown samples from Plate 1 to a standardcurve generated with OD readings of a serially diluted calibrator madeof known positive samples analyzed under the same conditions (withpeptide populations APL-ID1, APL-ID5.1, and APL-ID6). ^(b)platys Scorewas calculated by comparing OD readings of unknown samples from Plate 2to a standard curve generated with OD readings of a serially dilutedcalibrator made of known positive samples analyzed under the sameconditions (with peptide populations APL-ID5.1, and APL-ID6). ^(c)phagoWCL Score was calculated by comparing OD readings of unknown samplesfrom Plate 3 to a two point standard curve comprised of result from ahealthy dog's plasma sample (negative control) and result from a plasmasample from 3-13, a dog experimentally infected with A. phagocytophilum,analyzed under the same conditions (with A. phagocytophilum whole-celllysate). ^(d)Identification of the Anaplasma species infecting dogs inunknown samples using the Combo Score, platys Score, and phago WCLScore. Samples with Combo Scores of 9 or lower are classified asnegative for Anaplasma infection (“NEG”). Samples with Combo Scoreshigher than 9 are classified as positive for Anaplasma infection and theinfecting Anaplasma species are assigned by comparing the platys Scorewith the phago WCL Score--samples with higher platys Scores than phagoWCL Scores are classified as positive for A. platys infection(“platys”), and samples with lower platys Scores than phago WCL Scoresare classified as positive for A. phagocytophilum infection (“phago”).If a sample's platys Score is identical to its phago WCL Score, and itscombo score is greater than 9, the sample is classified as positive forAnaplasma infection with species indeterminate. ^(e)IDEXX SNAP 4DXPlus ™ assay was performed according to manufacturer's instruction.Percentages were calculated through densitometry analysis of images ofthe SNAP cassettes. They represent “(density of test sample)/(density oftest sample + density of positive control)”. ^(f)The IFA assay wasperformed with a commercial kit which used A. phagocytophilum cells todetect antibodies against Anaplasma. IFA titers were determined byserially diluting plasma samples and testing each dilution withimmobilized A. phagocytophilum cells.

The result in this Example demonstrates that the species of Anaplasmainfecting a subject can be successfully identified using the peptidepopulations and cell extract. In addition, a positive control samplefrom an A. phagocytophilum -infected dog, 3-13, was correctly identifiedin this Example (data not shown).

To the extent that any definitions in documents incorporated byreference are inconsistent with the definitions provided herein, thedefinitions provided herein are controlling. Although the invention hasbeen described with reference to the presently preferred embodiments, itshould be understood that various changes and modifications, as would beobvious to one skilled in the art, can be made without departing fromthe spirit of the invention. Accordingly, the invention is limited onlyby the following claims.

The disclosures, including the claims, figures and/or drawings, of eachand every patent, patent application, and publication cited herein arehereby incorporated herein by reference in their entireties.

The invention claimed is:
 1. A method for detecting in a sample anantibody to an epitope of an Anaplasma antigen, the method comprising:(i) contacting a sample with a composition comprising a population ofisolated peptides, said population comprising three or more differentpeptides, wherein each peptide in the population comprises a sequenceselected from: (a) SEQ ID NO: 1, wherein X₉ is an amino acid selectedfrom the group consisting of I, P and H, X₁₇ is an amino acid selectedfrom the group consisting of I, W, and Y, X₂₁ is an amino acid selectedfrom the group consisting of R, D, and N, X₂₈ is an amino acid selectedfrom the group consisting of E and N, and X₃₁ is an amino acid selectedfrom the group consisting of L and V; (b) SEQ ID NO: 2, wherein X₃ is anamino acid selected from the group consisting of L, V and A, X₇ is anamino acid selected from the group consisting of K, N and Q, X₁₁ is anamino acid selected from the group consisting of R, D, and N, and X₁₅ isan amino acid selected from the group consisting of E, N and Q; (c) SEQID NO: 3, wherein X₅ is an amino acid selected from the group consistingof V and A, X₇ is an amino acid selected from the group consisting of G,I and H, X₁₁ is an amino acid selected from the group consisting of E,N, and Q, X₁₈ is an amino acid selected from the group consisting of Dand N, X₂₁ is an amino acid selected from the group consisting of R, D,and N, X₂₅ is an amino acid selected from the group consisting of Q, D,and E, X₂₈ is an amino acid selected from the group consisting of and Eor N, X₃₁ is an amino acid selected from the group consisting of L andV, X₄₅ is an amino acid selected from the group consisting of K and Q,X₄₈ is an amino acid selected from the group consisting of F and V, X₅₁is an amino acid selected from the group consisting of D and N, X₅₄ isan amino acid selected from the group consisting of E and Q, X₅₇ is anamino acid selected from the group consisting of S and Q, X₆₀ is anamino acid selected from the group consisting of F and W, X₆₃ is anamino acid selected from the group consisting of I and V, and X₆₆ is anamino acid selected from the group consisting of Q and D; (d) SEQ ID NO:4, wherein X₆ is an amino acid selected from the group consisting of Kand Q, X₉ is an amino acid selected from the group consisting of F andV, X₁₂ is an amino acid selected from the group consisting of D and N,X₁₅ is an amino acid selected from the group consisting of E and Q, X₁₈is an amino acid selected from the group consisting of S and Q, X₂₁ isan amino acid selected from the group consisting of F and W, X₂₄ is anamino acid selected from the group consisting of I and V, and X₂₇ is anamino acid selected from the group consisting of Q and D; (e) SEQ ID NO:5, wherein X₂ is an amino acid selected from the group consisting of Iand V, X₁₀ is an amino acid selected from the group consisting of S andY, and X₂₃ is an amino acid selected from the group consisting of E andN; (f) SEQ ID NO: 6; (g) SEQ ID NO: 7, wherein X₅ is an amino acidselected from the group consisting of S and Q, X₉ is an amino acidselected from the group consisting of F and Y, X₁₃ is an amino acidselected from the group consisting of R and H, X₁₆ is an amino acidselected from the group consisting of W and Y, X₁₈ is an amino acidselected from the group consisting of S and Q, X₂₂ is an amino acidselected from the group consisting of K and H, and X₂₇ is an amino acidselected from the group consisting of N and D; (h) SEQ ID NO: 8, whereinX₁₀ is an amino acid selected from the group consisting of V, L and I,and X₁₁ is an amino acid selected from the group consisting of A and L;and (i) SEQ ID NO: 9, wherein X₅ is an amino acid selected from thegroup consisting of V and A, X₇ is an amino acid selected from the groupconsisting of G, I and H, X₁₁ is an amino acid selected from the groupconsisting of E, N, and Q, X₂₁ is an amino acid selected from the groupconsisting of R, D, and N, X₂₅ is an amino acid selected from the groupconsisting of Q, D, and E, X₂₈ is an amino acid selected from the groupconsisting of E and N, and X₃₁ is an amino acid selected from the groupconsisting of L and V; and (ii) detecting formation of anantibody-peptide complex comprising one or more of the three or moredifferent peptides in the composition, wherein formation of said complexis indicative of an antibody to an epitope of an Anaplasma antigen beingpresent in said sample.
 2. The method of claim 1, wherein said Anaplasmaantigen is from Anaplasma phagocytophilum, Anaplasma platys, orAnaplasma marginate.
 3. The method of claim 1, wherein the population ofisolated peptides is immobilized to a solid support optionally through ametallic nanolayer.
 4. The method of claim 1, wherein said detectingstep comprises (i) performing an ELISA assay, (ii) running a lateralflow assay, (iii) performing an agglutination assay, (iv) performing aWestern blot, a slot blot, or dot blot, (v) performing a wavelengthshift assay, (vi) performing an Indirect Fluorescent Antibody test , or(vii) running the sample through an analytical or centrifugal rotor. 5.The method of claim 1, wherein said sample is from a human, canine, orfeline subject.
 6. The method of claim 1, wherein said sample is ablood, serum, plasma, cerebrospinal fluid, tissue extract, urine, orsaliva sample.
 7. The method of claim 1, wherein one of the three ormore different peptides comprises SEQ ID NO:
 6. 8. The method of claim1, wherein one of the three or more different peptides comprises SEQ IDNO:
 3. 9. The method of claim 1, wherein the three or more differentpeptides comprise SEQ ID NOs: 3, 6, and
 7. 10. A method for diagnosinganaplasmosis in a subject, the method comprising: (i) contacting asample from the subject with a composition comprising a population ofisolated peptides, said population comprising three or more differentpeptides, wherein each peptide in the population comprises a sequenceselected from: (a) SEQ ID NO: 1, wherein X₉ is an amino acid selectedfrom the group consisting of I, P and H, X₁₇ is an amino acid selectedfrom the group consisting of I, W, and Y, X₂₁ is an amino acid selectedfrom the group consisting of R, D, and N, X ₂₈ is an amino acid selectedfrom the group consisting of E and N, and X₃₁ is an amino acid selectedfrom the group consisting of L and V; (b) SEQ ID NO: 2, wherein X₃ is anamino acid selected from the group consisting of L, V and A, X₇ is anamino acid selected from the group consisting of K, N and Q, X₁₁ is anamino acid selected from the group consisting of R, D, and N, and X₁₅ isan amino acid selected from the group consisting of E, N and Q; (c) SEQID NO: 3, wherein X₅ is an amino acid selected from the group consistingof V and A, X₇ is an amino acid selected from the group consisting of G,I and H, X₁₁ is an amino acid selected from the group consisting of E,N, and Q, X₁₈ is an amino acid selected from the group consisting of Dand N, X₂₁ is an amino acid selected from the group consisting of R, D,and N, X₂₅ is an amino acid selected from the group consisting of Q, D,and E, X₂₈ is an amino acid selected from the group consisting of and Eor N, X₃₁ is an amino acid selected from the group consisting of L andV, X₄₅ is an amino acid selected from the group consisting of K and Q,X₄₈ is an amino acid selected from the group consisting of F and V, X₅₁is an amino acid selected from the group consisting of D and N, X₅₄ isan amino acid selected from the group consisting of E and Q, X₅₇ is anamino acid selected from the group consisting of S and Q, X₆₀ is anamino acid selected from the group consisting of F and W, X₆₃ is anamino acid selected from the group consisting of I and V, and X₆₆ is anamino acid selected from the group consisting of Q and D; (d) SEQ ID NO:4, wherein X₆ is an amino acid selected from the group consisting of Kand Q, X₉ is an amino acid selected from the group consisting of F andV, X₁₂ is an amino acid selected from the group consisting of D and N,X₁₅ is an amino acid selected from the group consisting of E and Q, X₁₈is an amino acid selected from the group consisting of S and Q, X₂₁ isan amino acid selected from the group consisting of F and W, X₂₄ is anamino acid selected from the group consisting of I and V, and X₂₇ is anamino acid selected from the group consisting of Q and D; (e) SEQ ID NO:5, wherein X₂ is an amino acid selected from the group consisting of Iand V, X₁₀ is an amino acid selected from the group consisting of S andY, and X₂₃ is an amino acid selected from the group consisting of E andN; (f) SEQ ID NO: 6; (g) SEQ ID NO: 7, wherein X₅ is an amino acidselected from the group consisting of S and Q, X₉ is an amino acidselected from the group consisting of F and Y, X₁₃ is an amino acidselected from the group consisting of R and H, X₁₆ is an amino acidselected from the group consisting of W and Y, X₁₈ is an amino acidselected from the group consisting of S and Q, X₂₂ is amino acid fromthe group consisting of K and H, and X₂₇ is an amino acid selected fromthe group consisting of N and D; (h) SEQ ID NO: 8, wherein X₁₀ is anamino acid selected from the group consisting of V, L and I, and X₁₁ isan amino acid selected from the group consisting of A and L; and (i) SEQID NO: 9, wherein X₅ is an amino acid selected from the group consistingof V and A, X₇ is an amino acid selected from the group consisting of G,I and H, X₁₁ is an amino acid selected from the group consisting of E,N, and Q, X₂₁ is an amino acid selected from the group consisting of R,D, and N, X₂₅ is an amino acid selected from the group consisting of Q,D, and E, X₂₈ is an amino acid selected from the group consisting of Eand N, and X₃₁ is an amino acid selected from the group consisting of Land V; and (ii) detecting formation of an antibody-peptide complexcomprising one or more of the three or more different peptides in thecomposition, wherein formation of the complex is indicative of thesubject having anaplasmosis.
 11. The method of claim 10, wherein saidsubject is a human, canine, or feline.
 12. The method of claim 10,wherein one of the three or more different peptides comprises SEQ ID NO:6.
 13. The method of claim 10, wherein one of the three or moredifferent peptides comprises SEQ ID NO:
 3. 14. The method of claim 10,wherein the three or more different peptides comprise SEQ ID NOs: 3, 6,and 7.